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Abstract 
Identifying genes that encode APP metabolism 
modulators on chromosome 9q22  
 
Can Zhang  
Advisor: Aleister Saunders, Ph.D. 
 
 The central pathobiologic event in AD is regulated intramembrane 
proteolysis of the β-amyloid precursor protein (APP), which generates the 
amyloidogenic β-amyloid (Aβ) peptide and the APP intracellular domain (AICD). 
The AICD fragment displays transcriptional activation properties. The genetic 
cause of AD is not fully accounted for by the known risk genes, and recent 
meta-analysis suggests that there are around 20 unidentified genes. 
Chromosome 9q22 is implicated to harbor AD genes by human genome scan 
results. Here I constructed an AICD-mediated functional assay to discover 
novel APP metabolism regulators. 11 positional candidate genes have been 
identified on this region and their functions are undergoing further 
characterization. I found that Ubiquilin 1 modulates APP metabolism and this 
function is cell type dependent. I also found that Ubiquilin 1 can modulate cell 
viability and its degradation requires proteasome and lysosome.   
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CHAPTER 1 
Background  
 
CHAPTER1.1 
Introduction of Alzheimer’s disease   
 
AD, APP and Amyloid Hypothesis  
          Alzheimer’s disease (AD) is a progressive and degenerative disorder 
clinically characterized by progressive dementia that inevitably leads to 
incapacitation and death. AD is the most common form of dementia and affects 
40% individuals aged over 85. The majority of AD cases are late onset (>65 
years), this form is genetically complex[1]. The minority of AD cases (5-10%) 
are early-onset familial AD (FAD) with an autosomal dominant inheritance 
pattern[2, 3]. There are no effective therapies currently. Upon autopsy, massive 
synaptic loss and neuronal death is observed in brain regions critical for 
cognitive function, including cerebral cortex and hippocampus. There are two 
hallmarks that define AD at the microscopic level: (1) amyloid plaques, 
extracellular deposits primarily composed of the 4 kDa, 39–43 amino acid Aβ 
peptide[4-8], and (2) neurofibrillary tangles, intracellular aggregates of the 
microtubule associated protein tau[9-11]. The Aβ peptide is generated from an 
integral type I membrane protein β-amyloid precursor protein (APP)[12-15]. 
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Evidences from genetic and biochemical studies support the amyloid cascade 
hypothesis of AD which states that accumulation and aggregation of Aβ is the 
primary cause of AD. Aβ accumulation induces an inflammatory response 
followed by neuritic injury, hyperphosphorylation of tau protein and formation of 
fibrillary tangles, leading ultimately to neuronal dysfunction and cell death [16-
19]. Animal models which reproduce AD pathology and develop amyloid 
deposits show learning deficits reminiscent of those of humans affected with 
the disease. Animal models studies that decrease neuronal Aβ burden using 
passive or active immunization can also ameliorate learning deficits of affected 
animals [20-22]. Thus, prevention of Aβ production and accumulation is 
currently being evaluated as a potential therapeutic intervention for AD.  
α-, β-, And γ-secretases.  
            Aβ peptide is proteolytically cleaved from APP by several different 
proteases called α-, β-, and γ- secretase. Figure 1-1 and 1-2 are the schematic 
overview of APP processing by the α-, β-, and γ-secretases. This will be also 
described in my first review paper. Figure 1-1 shows the amino acid sequence 
of β amyloid precursor protein (APP) upstream of the transmembrane segment 
(underlined, bold) and encompassing the sequences of Aβ 1-40 and Aβ 1-42 (D1-
V40 and D1- A42, respectively). The β -secretase cleaves at D1. The -secretase 
cleaves at Lys16, and the γ-secretase cleaves at Val40 and/or Ala42. Aβ (1-40) is 
soluble, which accounts for approximately 90% of the total Aβ secreted. Aβ (1-
42) is insoluble, and it accounts for approximately 10% of the total Aβ secreted. 
However, Aβ (1-42) constitutes the major component of the nonfibrillar 
extracellular plaques that precede the development of the dense, fibrillar 
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neuritic plaques characteristic of AD[23]. The left side of Figure 1-2 represents 
the nonamyloidogenic pathway in which sAPPα and C83 are generated. 
Subsequent hydrolysis by the γ-secretase produces a p3 peptide and APP 
intracellular domain (AICD). The right side of Figure 1-2 represents the 
amyloidogenic pathway in which sAPPβ and C99 are liberated. Subsequent 
hydrolysis by the γ-secretase releases Aβ found in plaque deposits and AICD. 
Proteolysis by γ-secretase is heterogeneous, which produces different length 
Aβ species, with longer and more hydrophobic species more prone to fibril 
formation.  
 
          
Figure 1-1 Amino acid sequence of Aβ in APP695 and the cleavage site of α-, β-, 
and γ-secretases.   
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Figure 1-2 Schematic overview of APP processing by the α-, β-, and γ-
secretases. 
        Several proteins from the adamalysin family have α-secretase activities, 
and they are tumour necrosis factor-alpha convertase (TACE, or ADAM17), 
ADAM10, and ADAM9[24-27]. ADAMs (A Disintegrin And Metalloprotease 
domain) are multifunctional, membrane-bound cell surface glycoproteins, which 
have been implicated in cell adhesion, protein ectodomain shedding, matrix 
protein degradation and cell fusion. [28-32];[33, 34]. Some ADAMs have a 
consensus zinc-binding motif, HEXXH, in the catalytic domain. In addition to 
cleaving APP, ADAM 10 and ADAM 17 are both implicated in the ectodomain 
shedding of various cell surface molecules including the Notch, the IL6-receptor 
and the transmembrane chemokines CX3CL1 and CXCL16. These molecules 
are constitutively released from cultured cells, a process that can be rapidly 
induced by cell stimulation with phorbol esters such as PMA (phorbol 12-
myristate 13-acetate)[35]. Recent research supports the view that the 
constitutive cleavage predominantly involves ADAM10 while the inducible one 
is mediated to a large extent by ADAM17. Mice with ADAM17ΔZn/ΔZn null 
mutation died at birth with phenotypic changes, including failure of eyelid fusion, 
hair and skin defects, and abnormalities of lung development[36]. TAPI-1 (TNF-
α protease inhibitor -1) blocks cleavage of cell surface TNF and inhibits 
constitutive sAPPα release [37]. TAPI-2 and 1,10-phenanthroline, which are 
known to inhibit metalloproteases, block PMA-activated shedding of proTGF-α, 
cell adhesion receptor L-selectin, interleukin 6 (IL-6) receptor α subunit, and 
APP[38].   
 16
         β-site APP cleaving enzyme (or β-secretase, BACE, BACE1, Asp2 or 
memapsin 2) is a member of the pepsin family of aspartyl proteases [39-44]. It 
is a type 1 transmembrane protein, which has an N-terminal catalytic domain, 
containing two catalytic aspartic residues, linked to a 17-residue 
transmembrane domain and a short C-terminal cytoplasmic tail. Within the cell, 
BACE is expressed initially as a preproprotein, and then efficiently processed to 
its mature form in the Golgi. To date, no mutations in the BACE gene have 
been identified that strongly associate with AD. BACE activity is present in the 
majority of cells and tissues, while maximal activity is found in neural tissue and 
neuronal cell lines. BACE has maximal activity at acidic pH, and its activity is 
highest in the acidic subcellular compartments of the secretary pathway, 
including the Golgi apparatus and endosomes. With the discovery of BACE, 
another human homologue was identified and called BACE2. BACE2 is not 
highly expressed in the brain, and the lack of any detectable Aβ in BACE−/− 
animals suggests that BACE2 does not contribute to the generation of Aβ [45]. 
The studies of BACE knockout mice showed that β-secretase activity was 
abolished in brains and cultured neurons of BACE−/− mice [46, 47]. All the 
knockout strategies produce viable, fertile BACE deficient (BACE−/−) mice, 
which appear to develop normally and have no discernable abnormalities 
compared to BACE+/+ mice. Moreover, investigations of gross behavioral and 
neuromuscular parameters of BACE−/− mice demonstrate no obvious 
differences with wild-type mice. And transgenic BACE expression in mouse 
neurons can accelerate amyloid plaque pathology [48]. With the discovery of 
BACE, another human homologue was identified and called BACE2 ([49]). 
BACE2 is not highly expressed in the brain, and the lack of any detectable Aβ 
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in BACE−/− animals suggests that BACE2 does not contribute to the generation 
of Aβ [45].  
          γ-secretase cleaves APP using a novel proteolytic mechanism, termed 
regulated intramembrane proteolysis (RIP) [50]. Four membrane proteins are 
now well known to be members of γ-secretase complex: presenilin (PS1), 
presenilin enhancer-2 (PSEN2), nicastrin (NCSTN) and anterior pharynx 
defective-1 (APH-1)[51, 52]. Recently CD147 is found to exist as a regulatory 
subunit of the γ-secretase complex, and it down-regulates Aβ production. [53]. 
Evidence suggests that PS (PS1 and PS2) are aspartyl proteases that are 
active in RIP. A number of different functions have been ascribed to PS, 
including a role in promoting or reducing the susceptibility of neurons to 
apoptosis [54] and regulating intracellular calcium signaling and calcium-
mediated apoptosis [55, 56]. The well substantiated functions for PS are γ-
secretase cleavage of APP and Notch [57, 58]. The Notch protein functions as 
a receptor at the cell surface and mediates cell cell signaling interactions to 
specify cell fates within an equivalence group, a role that is particularly 
important during development. Notch is activated by a proteolytic cascade 
similar to that of APP. The PS1/2 double homozygous deficient knockout (KO) 
mouse displays a number of severe phenotypes that are similar to the 
Notch1−/− mouse [59]. A role for PS in APP metabolism was suggested from 
observations that PS familial AD (FAD) mutations cause an increase in the ratio 
of Aβ42: Aβ42+40, indicating altered processing at the γ-secretase cleavage 
site. PS FAD overexpression assays in tissue culture systems confirmed the 
FAD increase in the ratio of Aβ42: Aβ42+40 [60]. Transgenic mice that express 
mutant PS transgenes display elevated brain Aβ levels but do not develop 
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neuritic plaques [61]. However, mice that overexpress both a PS1 FAD mutant 
and the APPsw mutant (APP Swedish mutation KM595/596NL) show 
accelerated Aβ deposition compared with mice expressing the APPsw mutant 
alone). PS1-deficient mice (PS1−/−) have retarded embryonic growth and die 
shortly before or immediately after birth [62]. Re-introduction of wild-type (wt)-
hPS1 or FAD-hPS1 equivalently rescues the PS1−/− mice from embryonic 
lethality (Davis et al. 1998; Qian et al. 1998). Unlike PS1−/− mice, PS2−/− mice 
are viable, fertile and have no detectable abnormalities in APP metabolism. 
The only phenotype identified in the PS2−/− mouse was the development of mild 
pulmonary fibrosis and hemorrhage as the animals aged [59]. These results 
directly implicate PS as the γ-secretase enzyme or an essential co-factor for γ-
secretase cleavage of APP C99/C83. L-685,458 is a novel, potent and 
selective cell-permeable γ-secretase inhibitor[63-65]. It exhibits over 100-fold 
greater selectivity for γ-secretase than for a panel of other proteases.  [63]   
And it potently inhibits γ -secretase and thus the production of Aβ total (IC50 17 
nM), Aβ (1-40), (IC50 48 nM) and Aβ (1-42) (IC50 67nM) in human 
neuroblastoma SH-SY5Y cells overexpressing spbA4CTF, a truncated form of 
human APP. 
         In addition to generating Aβ peptide, γ- secretase cleavage of APP 
produce APP intracellular domain (AICD). AICD forms a transcriptionally active 
complex containing the nuclear adaptor protein Fe65 and the histone 
deacetyltransferase TIP60 [66]. This complex targets, for example, the KAI1 
promoter. Ehrmann and Clausen reported a genetic system to monitor and 
investigate γ-secretase function and assembly [67]. The system involves 
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coexpression of γ- secretase and a APP C-terminal fragment (CTF) of 55 
residues, including the transmembrane segment, fused to the Gal4 
transcriptional activator. Proteolytic processing of the reporter protein releases 
the Gal4 domain from the membrane from where it translocates to the nucleus 
and activates transcription of the promoter that drives expression of the 
reporter gene lacZ.  lacZ, encoding β-galactosidase, provides a quantitative 
output signal that correlates with the activity of γ-secretase. This system might 
allow mutational approaches to study such important questions as substrate 
specificity and the identification of processes that regulate γ-secretase activity. 
For example, random mutagenesis of genes encoding γ- secretase 
components could be used to identify which components are involved in 
excluding full-length APP from processing.  
        
AD 
Type 
Genes Genetic 
Mechanism 
Chromo- 
some 
Biological 
Mechanism 
 
Early 
Onset 
APP 
PSEN1 
PSEN2 
 
13 
150 
7 
21 
14 
1 
 
APP metabolism 
Late  
Onset 
APOE 
 
ε4 19 APP metabolism 
 
          Table 1-1:  Known genes that modulate AD risk. Early onset AD can 
be caused by any of over 150 mutations in three known genes (APP, PSEN1, 
and PSEN2). A common polymorphism in the gene encoding apolipoprotein E 
(APOE) confers increased risk for late-onset AD. Human AD genome scan 
demonstrated multiple chromosomes harbor AD putative genes.  Their 
expressed proteins may interact with each other, and may influence Aβ 
degradation and clearance.  
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Genetic studies of AD 
           There are two forms of AD: early onset and late onset (Table 1-1). Early 
onset can be caused by any one of over 150 mutations in three known genes 
[1]: the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 
(PSEN2). A common polymorphism ( 4) in the gene encoding apolipoprotein E 
(APOE) confers increased risk for late-onset AD [68], and lowers the age of 
onset in a dose-dependent fashion [69, 70]. There are more than 100 high risk 
genes reported for late onset, but they were not universally confirmed mostly 
due to the failure of replication. Genetic and epidemiological studies have 
shown that genes beyond APOE are involved in disease etiology. Simulation 
studies estimated that up to 4 additional major genes as well as several minor 
AD genes remain to be identified [71, 72]. Kehoe et al have genotyped 292 
affected sibling pairs (ASPs) with AD with onset ages of >/=65 years using 237 
microsatellite markers separated by an average distance of 16.3 cM[73]. They 
found the highest lod scores on chromosomes 1, 9, 10 and 19. Myers et al 
performed a two-stage genome screen to search for novel risk factors for late-
onset Alzheimer disease (AD) [74]. They found 10 peaks on chromosomes 1 
(peak B), 5, 6, 9 (peaks A and B), 10, 12, 19, 21, and X.  In 2003, Blacker et al 
performed a 9cM genome screen of 437 families with AD[75] from the full 
National Institute of Mental Health (NIMH) sample, which had been carefully 
ascertained, evaluated and followed over the last decade. They observed a 
'highly significant' linkage peak on chromosome 19q13, which probably 
represents APOE. Twelve additional locations (on 1q23, 3p26, 4q32, 5p14, 
6p21, 6q27, 9q22, 10q24, 11q25, 14q22, 15q26 and 21q22) met criteria for 
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'suggestive' linkage. While some of the more marginal peaks in the study 
probably represent false-positive findings, others, particularly those with 
relatively stronger signals and/or prior reports (e.g. on chromosomes 9q22), are 
more likely to harbor genuine AD susceptibility genes.  
RNAi  
          Recently, gene silencing by RNA interference (RNAi) in mammalian cells 
using small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) has 
become a valuable genetic tool. [76-78] [79]; [80]; [81]; [82]; [83]; [84]; [85];[86]. 
The phenomenon of RNA interference (RNAi) was first described by Fire et al. 
eight years ago[87]. They observed that the response to double-stranded RNA 
(dsRNA) in the nematode, Caenorhabditis elegans, resulted in potent 
sequence-specific gene silencing at the post-transcriptional level. The complete 
spectrum of biological processes in which the RNAi machinery acts is far from 
clear. However, it has been suggested that the RNAi is an RNA-based cellular 
‘immune system', and is an evolutionarily conserved mechanism for combating 
viruses or parasitic endogenous genetic elements. Mechanistically, RNAi is a 
two-step process. In the first step, the dsRNA that triggers the silencing 
response is cleaved into small interfering RNAs (siRNAs) [88] of 21–23 
nucleotides. This is accomplished by Dicer, an RNase-III-family nuclease. In 
the second step, siRNAs are incorporated into a targeting complex, known as 
RISC (RNA-induced silencing complex), which destroys mRNAs that are 
homologous to the integral siRNA [89]. The RNAi gene knockdown technique is 
developed after discovering microRNA (miRNA) features. MiRNAs are small 
noncoding RNA gene products about 22 nt long that are processed by Dicer 
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from precursors with a characteristic hairpin secondary structure [90-93]. 
miRNAs are produced by Dicer from the precursors of approximately 70 
nucleotides (pre-miRNAs), these clustered miRNAs are expressed 
polycistronically and are processed through at least two sequential steps: (i) 
generation of the approximately 70 nucleotide pre-miRNAs from the longer 
transcripts (termed pri-miRNAs); and (ii) processing of pre-miRNAs into mature 
miRNAs. Subcellular localization studies showed that the first and second steps 
are compartmentalized into the nucleus and cytoplasm, respectively, and that 
the pre-miRNA serves as the substrate for nuclear export. Lee’s study (Lee et 
al. 2002) suggested that the regulation of miRNA expression may occur at 
multiple levels, including the two processing steps and the nuclear export step. 
Over a hundred miRNA genes have been discovered so far from biochemical 
and bioinformatic studies of Caenorhabditis elegans, Drosophila melanogaster 
and Homo sapiens.  
        siRNA is 21 bp in length and is essentially chemically synthesized RNAs 
that mimics of Dicer cleavage products. These small RNAs have been shown 
to induce sequence-specific gene silencing when transiently transfected into 
mammalian cells. shRNA uses expression constructs harboring a 19–29 bp 
inverted repeat that forms a short hairpin when transcribed in vivo. It 
reproduces the secondary structure of endogenous interfering RNAs (micro 
RNAs). The short hairpin RNA (shRNA) constructs are expressed as human 
microRNA-30 (mir-30) precursors (Paddison et al. 2004). The mir-30-styled 
shRNA is synthesized as a single stranded DNA oligo with common ends 
corresponding to part of the endogenous mir-30 miRNA flanking sequence. 
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These common sequences are used to prime a PCR reaction, whereby the 
entire mir-30-styled shRNA is amplified to produce a clonable PCR product. 
Significance 
          Alzheimer's disease (AD) is a devastating neurodegenerative disorder of 
late life with complex inheritance. The molecular mechanisms of are is still not 
complete understood; there are still up to 4 genes to be identified. And there 
are no effective therapies that can modify the process the disease. Our 
research is aimed at utilizing an AICD mediated reporter gene assay system to 
identify novel modulators of APP processing on chromosome 9q22. The 
substantial effort required to identify and characterize as many of AD risk genes 
as possible will help us better understand APP processing pathway, and will 
greatly facilitate the development of strategies for treatment, early intervention, 
and prevention of this devastating disease.   
Specific Aims  
           Alzheimer’s disease (AD) is a progressive and degenerative disorder, 
which is clinically characterized by progressive dementia that inevitably leads to 
incapacitation and death. The central pathobiologic event in AD is the regulated 
intramembrane proteolysis (RIP) of the β-amyloid precursor protein (APP), 
which generates the amyloidogenic β-amyloid (Aβ) peptide and the 
transcriptionally active APP intracellular domain (AICD). Excessive Aβ 
accumulation in the neurons is believed to be the primary cause of the disease. 
The genetic cause of AD is not fully accounted for by the known risk genes, 
and studies show there are around 4-7 other genes that contribute to the 
disease [72]. Five independent genome scan showed more than 10 
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chromosome regions may contain AD candidate genes. Chromosome 9q22 
(75Mb to 110Mb) is implicated in three of the five genome scans[73-75], and 
has constantly high LOD scores. Since APP processing is the central event of 
AD, AD risk genes may play an important role in APP processing. This 
proposal is aimed at identifying novel modulators of APP processing on 
chromosome 9q22, a region that is suggested to contain AD risk genes. 
Identifying novel modulators will increase our understanding of APP processing, 
and illuminate new avenues for therapeutic intervention. There are five specific 
aims in this research.  
          1. Constructing and validating the AICD - mediated luciferase reporter 
gene assay system. In the APP differential processing pathway, APP is cleaved 
by α or β- secretase, which produces differential N- and C- termini. Then the C-
terminus products are further cleaved by γ- secretase, which releases Aβ, P3 
and AICD. Since AICD can enter nucleus and activate gene expression, we will 
construct a cell based assay in which luciferase gene expression level is 
regulated by AICD levels. We will validate that luciferase gene expression is 
regulated in concordance with known APP processing pathways. α-, β-, and γ- 
secretase inhibitors and stimulators which regulate APP proteolytic pathway will 
be used to validate this assay system. Once validated, this assay system will 
be used to identify novel modulators of APP processing. 
          2. Establishing shRNA technology. The technology of short hairpin RNAs 
(shRNAs) has become a valuable genetic tool, which allows us to inhibit 
specific genes and study their functions in mammalian cells[76, 94-96]. Now a 
shRNA expression library targeting human genome has been established and 
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constructed into retrovirus packaging vectors. These shRNA expression 
constructed are based on plasmid and contain puromycin resistance. We will 
transfect them into our assay cells and select with puromycin. Transfection 
efficiency is a crucial issue of the shRNA effects; we will compare available 
transfection reagents, and will optimize the one that have the highest 
transfection efficiency. 
          3. Identifying novel modulators of APP processing. After we have 
validated our AICD mediated luciferase gene assay system and established 
shRNA technology in our laboratory, we will knock down positional candidate 
genes on chromosome 9q22 in our assay system. The choice of chromosome 
9q22 is from human AD genome screens which suggest that this region harbors 
AD high risk genes. Luciferase activity will be monitored. The shRNAs that 
modulate luciferase activity may be involved in APP processing, and their 
genes should be considered putative AD genes. To confirm the putative AD 
genes can modulate APP processing, overexpression of those genes will be 
carried out.  
          4. Characterize mechanisms by which novel modulators alter APP 
processing. The modulaotrs may influence APP processing by affecting α-, β-, 
and γ- secretases, and other mechanisms as well. To study how the novel 
regulators modulate APP processing, we will measure substrates and products 
that are involved in APP processing. We will examine α-, β-, and γ- secretases 
level alteration. Characterization of APP processing by those modulators may 
illuminate new avenues for therapeutic intervention.  
 26
 
CHAPTER 1.2 
Therapeutic targeting of the α-secretase pathway to  
treat Alzheimer’s disease 
 
Can Zhanga, Aleister J. Saundersa,b 
 
a- Department of Bioscience & Biotechnology, Drexel University, Philadelphia, PA 
b- Department of Biochemistry & Molecular Biology, Drexel University College of 
Medicine, Philadelphia, PA 
 
        Alzheimer’s disease (AD) is a progressive and degenerative disorder 
pathophysiologically characterized by beta-amyloid peptides (Aβ) 
accumulation in the brain. Aβ is indicated to be the primary agent in the 
pathogenesis of AD. Aβ is generated from the amyloid precursor protein 
(APP) via two proteolytic activities, β-, and γ- secretases. α-Secretase 
cleavage is an alternative proteolytic cleavage which prevents Aβ 
production and deposition. Elevating α-secretase activity, therefore, is a 
potential therapeutic strategy to treat AD.  
 
        Introduction  
          Alzheimer’s disease (AD) is a progressive and degenerative disorder 
clinically characterized by dementia that inevitably leads to incapacitation and 
death. It was named after Dr. Alois Alzheimer by colleagues after he first 
described the disorder in 1907. AD is the most common form of dementia and 
affects about 40% individuals aged over 85. More than 5 million Americans now 
have AD. There is currently no cure to stop disease progression. 5-10% AD 
cases are classified as early-onset AD, defined by an age of onset of 60 or less. 
More than 160 mutations in three genes (APP, PSEN-1, and PSEN-2) have 
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been identified that cause this form of disease [1]. These mutations are 100% 
penetrant which means any individual mutation will definitely cause early onset 
of AD. Given this strong genetic cause, this form of the disease is often referred 
to as familiar AD. On the other hand, 90-95% of AD cases are late onset (>65 
years). Advanced age and a family history of the disease are the largest risk 
factor for this form of AD. Genetically, common polymorphisms increase the 
risk of developing AD. Polymorphisms in one gene, APOE, have been 
repeatedly confirmed to modulate AD risk. Specifically the APOEε4 allele 
increases AD risk. Recent meta-analysis results suggest that AD risk is 
modulated by numerous genes (~25), each displaying a small yet significant 
effect on risk. In addition to age and genetics, environmental factors such as 
diet, smoking, education also modulate risk of developing late onset AD.  
           The underlying mechanism of AD pathogenesis is still not completely 
understood. At the microscopic level, AD is characterized by two obvious 
pathological hallmarks: (1) amyloid plaques, primarily composed of the 39–43 
amino acids Aβ peptide; and (2) neurofibrillary tangles, paired helical filaments 
of hyperphosporylated Tau protein. A large amount of genetic, cell biology and 
biochemical evidences support the amyloid cascade hypothesis of AD 
pathogenesis. This hypothesis states that Aβ production and accumulation is 
the primary cause of AD. Soluble Aβ affects synaptic functions. Accumulated 
insoluble Aβ induces an inflammatory response followed by neuritic injury, 
hyperphosphorylation of tau protein and formation of fibrillary tangles, leading 
ultimately to neuronal dysfunction and cell death[1, 16, 97]. The Aβ peptide is 
generated from an integral type I membrane protein β-amyloid precursor 
protein (APP). Thus, genes and proteins that can modulate APP metabolism 
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and decrease Aβ production and deposition are currently envisioned as good 
targets for AD therapeutics. 
           APP metabolism- amyloidogenic and non-amyloidogenic pathways  
           APP is a transmembrane protein with a long extracellular or luminal 
domain, a transmembrane domain and a short cytoplasmic domain (Figure 1-1 
& 1-2). APP gene is localized on chromosome 21.  APP mRNA undergoes 
alternative splicing to yield eight possible isoforms, three of the APP isoforms 
(the 695, 751 and 770 amino acid isoforms) predominate in the brain. APP695 is 
produced mainly in neurons; APP751 and APP770 are found mostly in non-
neuronal glial cells. 
          APP can undergo sequential proteolytic cleavage (Figure 1-1 & 1-2). 
Depending on whether Aβ is generated, the pathway is termed amyloidogenic 
or non-amyloidogenic. In the amyloidogenic pathway, the protease that first 
cleaves APP is β-secretase. This extracellular cleavage yields soluble N-
terminal APP (or sAPPβ) and a transmembrance C-terminal fragment (β-CTF). 
β-CTF is then cleaved within the membrane by γ-secretase and generates Aβ 
and APP intracellular domain (AICD). Depending on the γ-secretase cleavage 
site, there are two main Aβ species generated: Aβ40 and Aβ42. In the 
physiological state, there are much more Aβ40 than Aβ42. However in amyloid 
plaques, more Aβ42 is found than Aβ40. β-secretase is encoded by a gene 
named BACE or BACE1, and is a member of the pepsin family. Like APP, 
BACE is also a transmembrane protein, which has an extracellular N-terminal 
domain, containing two catalytic aspartic residues, linked to a transmembrane 
domain and a short cytoplasmic C-terminal domain. BACE2, a BACE1 
homologue, has both β-secretase and α-secreatase activities. γ-secretase is a 
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member protein complex, which contains five membrane proteins: presenilin 
(PSEN), presenilin enhancer-2 (PEN2), nicastrin (NCSTN), APH-1 and CD147.  
 In the non-amyloidogenic pathway, the protease that first cleaves APP is 
α -secretase. This cleavage occurs in the middle of the Aβ region and yields 
soluble N-terminal APPα (sAPPα) and a transmembrane C-terminal fragment 
(α-CTF). sAPPα has neurotrophic and neuroprotective functions. Similar to β-
CTF, α-CTF is then cleaved by γ-secretase to generate P3, instead of Aβ, and 
AICD. Three enzymes have been shown to harbor α-secretase activity: ADAM9, 
ADAM10 and ADAM17 (also named as tumour necrosis factor-α convertase or 
TACE). They all belong to the family of ADAMs (A Disintegrin And 
Metalloprotease domain), which are multifunctional, membrane-bound cell 
surface glycoproteins, which have been implicated in cell adhesion, protein 
ectodomain shedding, matrix protein degradation and cell fusion.   
           The currently approved medicine in the U.S. only treats the symptoms, 
particularly cognitive deficit, but not the underlying cause of AD, APP 
proteolysis and Aβ accumulation. Four drugs, Tacrine (Cognex), donepezil 
(Aricept), galantamine (Reminyl), and rivastigmine (Exelon), belong to 
cholinesterase inhibitors that can suppress the enzymatic hydrolysis of 
neurotransmitter acetylcholine, thus maintain a higher acetylcholine 
concentration in the neuronal synapse [98]. Another drug, Memantien (Axura), 
is a moderate affinity NMDA-receptor antagonist.  
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Figure 2-1A Schematic overview of APP processing by the α-, β-, and γ-
secretases. 
         
           Inhibition of amyloidogenic processing is an obvious therapeutic 
approach to treating AD. Indeed, compounds that inhibit β- or γ-secretase are 
in clinical trials currently. Other treatments that target Aβ production and 
accumulation are also under active investigation, and include α-secretase 
stimulation, immunotherapy, selective Aβ42-lowering agents (tarenflurbil), 
inhibitors of amyloid aggregation (tramiprosate), and cholesterol-lowering agent 
(statins). Some of them have reached phase III clinical trials and some trials 
have failed due to the safety and adverse actions. Among these strategies, 
stimulating α-secretase is the only direct gain-of-function strategy and appears 
to be the safest strategy because sAPPα is indicated to be neurotrophic and 
neuroprotective. Our group and some other groups showed that ADAM9, 
ADAM10 and ADAM17 are constitutively expressed; in addition, the activities of 
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ADAM10 and ADAM17 can be stimulated by a number of signal transduction 
pathways including protein kinase C (PKC), phospholipase A2 (PLA2) and 
muscarinic acetylcholine receptors (mAChRs). Therefore genes and pathways 
that stimulate α-secretase activities should be considered good therapeutic 
targets. The rest of this review will discuss the current progress of identifying 
genes that can modulate α-secretase activity and the progress characterizing 
α-secretase stimulators.  
            Genes and proteins that can modulate α- secretases activity  
           The results of genetic linkage and association studies have been very 
useful in identifying the genes, proteins, pathways involved in AD pathogenesis. 
These approaches have also identified α-secretase modulators.  
  N-arginine dibasic convertase (NRDc or Nardilysin) is a peptidase which 
hydrolyses peptide substrates on the N-terminus of arginine residues. The 
gene Nardilysin is located on chromosome 1p32, a genomic region implicated 
to harbor an AD locus from linkage studies[75]. The nardilysin protein 
enhances the α-secretase activity directly by regulating ADAMs and decreases 
the generation of Aβ using unidentified mechanism. The nardilysin protein is 
expressed in adult heart, skeletal muscle, testis and cortical neurons of the 
human brain.   
            CYP46A1 (cytochrome P450, family 46, subfamily a, polypeptide 1) is 
another gene whose encoded protein can elevate α-secretase activity indirectly. 
The gene is located on the chromosome 12 in a region linked to AD, and 
polymorphisms within the gene have been associated with increased AD risk. 
CYP46A1 encodes the protein cholesterol 24- hydroxylase, which is expressed 
almost exclusively in the brain. Cholesterol 24-hydroxylase catalyzes 
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cholesterol into 24S-hydroxycholesterol (24S-OHC), which is a major pathway 
for excess cholesterol to efflux from the brain. In AD, the levels of 24S-OHC in 
the brain are decreased, therefore, brain can not excrete excess cholesterol 
and more cholesterol remains in the brain. This year Famer el al. found that 
24S-OHC increases the α-secretase activity as well as the α/β-secretase 
activity ratio. So when the brain 24S-OHC level is low in AD cases, the 
cholesterol level in the brain is high, α-secretase activity decreases and β-
secretase activity increases comparatively. Famer et al suggested up-
regulation of CYP46A1 could be a possible strategy for AD drug development.  
          Numerous lines of investigations indicate that α-secretase activity can 
also be regulated by neurotransmitters and their receptors, particularly G-
protein coupled receptors (GPCRs). GPCRs are a family of conserved proteins 
that contain seven transmembrane domains whose functions are diverse but 
primarily function to transduce extracellular stimuli into the nuclei of the cells 
and induce transcription of target genes. GPCRs are of such clinical 
significance that nearly 50% of all drugs target GPCRs. Interestingly but not 
surprisingly it was recently found that APP processing is also controlled by 
GPCRs. Specifically, α-secretase activity can be modulated by GPCRs, like 
muscarinic acetylcholine receptors (mAChR), metabotropic glutamate receptor 
(mGluR) and purinergic receptor P2Y2. The underlying mechanism is still not 
completely identified but it appears that GPCRs sense the extracellular 
changes, including cholesterol levels, reactive oxygen species (ROS), hypoxia, 
and free nucleotide and then transduce these signals to the interior of the cells 
and induce the transcription of kinases and α -secretase. For example after M1 
(a subtype of mAChRs) is activated by its agonist AF267B, protein kinase C 
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(PKC), phospholipase A2 (PLA2) , in turn ADAM17 is activated, stimulating 
APP processing preferentially toward non-amyloidogenic pathway. Animal 
models have also been demonstrated that AF267B can reduce Aβ deposition 
and rescue the cognitive deficits.  
           To systematically identify proteins that modulate APP proteolysis, 
particularly the initial cleavage by α-, or β- secretase, Lichtenthaler and his 
group carried out an expression cloning screen last year. In addition to protein 
kinase A, a already known activator, they also identified the following proteins: 
the endocytic proteins endophilin A1 and A3, the metabotropic glutamate 
receptor 3 (mGluR3), palmitoyl-protein thioesterase 1 (PPT1), Numb-like and 
the kinase MEKK2. Endophilin A3 demonstrated the strongest activity of APP 
shedding, which specifically increased sAPPα secretion and nonspecifically 
reduced the rate of APP endocytosis. The gene encoding Endophilin A3 is 
SH3GL3 (SH3-domain GRB2-like 3), which is located on the chromosome 
15q25. This region is near a genomic region (15q26) linked to AD. Endophilin 
A3 contains 347 amino acids and is preferentially expressed in the brain and 
testis. It can selectively interacts with the HDex1p (HD exon 1 protein) and 
promotes the formation of insoluble polyglutamine-containing aggregates. It is 
suggested to be involved in the neuronal death and pathophysiology of 
Huntington’s disease.  
          Numerous lines of research have indicated that elevation of non-
amyloidogenic pathway is a promising therapeutic strategy for the treatment of 
AD. Some potential therapeutics and lead compound exist already.  Specifically 
a benzolactam derivative, TPPB [(2S,5S)-(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-
2,4-pentadienoylamino) benzolactam]  is a novel α-secretase activator that 
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functions by stimulating the PKC pathway with unidentified mechanism. It shifts 
APP processing towards the non-amyloidogenic pathway by increasing α-
secretase activity, as well as decreases β-secretase activity and Aβ40 levels. 
An extract from green tea, EGCG, [Green tea polyphenol (-)-epigallocatechin-3-
gallate] reduces brain Aβ levels by increasing α-secretase activity, specifically 
ADAM10, but does not significantly alter β-or γ-secretase activities. Other 
examples include acetylcholinesterase inhibitors (AChEIs), 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA) inhibitors (belonging to cholesterol 
lowing agents, like statins) and nonsteroidal anti-inflammatory drugs (NSAIDs). 
Besides their original primary effects, they all can stimulate α-secretase activity, 
and some may also inhibit β and/or γ activity as well. Donepezil (belonging to 
AChEIs) increases α-secretase secretion by promoting ADAM10 trafficking 
and/or maturation. NSAIDs and statins exert functions by modulation of the 
isoprenoid pathway and Rho-associated protein kinases (ROCKs), particularly 
ROCK1 activities, as well as by modulation of inflammatory reactions and 
cytokine secretions. It has been well known that caloric restriction (CR) can 
expand life span and recent findings suggest that CR may be beneficial to AD 
intervention.  by increasing sAPPα. The underlying mechanism involves SIRT1, 
the NAD+-dependent sirtuin, whose encoding gene lies on chromosome 10, a 
genetic region linked to AD. CR, as well as resveratrol, an agonist of SIRT1 can 
dramatically increase sAPPα. This process can be potentially derived from the 
increase of ADAM10 levels. Resveratrol is an extract from red wine; therefore, 
selecting food intake should be considered an intervention of AD.  
         These examples suggest that therapeutically targeting the α-secretase 
pathway is a viable option fro treating AD. α-secretase have other membrane 
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protein substrates other than APP. More research is needed to investigate the 
effects apart from APP upon α-secretase stimulation. Detailed understanding of 
the underlying mechanisms of these α-secretase modulators of APP 
processing, as well as identifying novel and specific α-secretase modulators will 
open up novel avenues for the therapeutic intervention of AD. 
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Abstract 
Background. A central event in Alzheimer’s disease (AD) is the regulated 
intramembraneous proteolysis of the β-amyloid precursor protein (APP), to 
generate the β-amyloid (Aβ) peptide and the APP intracellular domain (AICD). 
Aβ is the major component of amyloid plaques and AICD displays 
transcriptional activation properties. We have taken advantage of AICD 
transactivation properties to develop a genetic screen to identify regulators of 
APP metabolism. This screen relies on an APP-Gal4 fusion protein, which upon 
normal proteolysis, produces AICD-Gal4. Production of AICD-Gal4 induces 
Gal4-UAS driven luciferase expression. Therefore, when regulators of APP 
metabolism are modulated, luciferase expression is altered.  
Results. To validate this experimental approach we modulated α-, β-, and 
γ-secretase levels and activities. Changes in AICD-Gal4 levels as measured by 
Western blot analysis were correlated to the observed changes in AICD-Gal4 
mediated luciferase activity. To determine if a known regulator of APP 
trafficking/maturation and Presenilin1 endoproteolysis could be detected using 
the AICD-Gal4 mediated luciferase assay, we knocked-down Ubiquilin 1 and 
observed decreased luciferase activity. We confirmed that Ubiquilin 1 
modulated AICD-Gal4 levels by Western blot analysis and also observed that 
Ubiquilin 1 modulated total APP levels, the ratio of mature to immature APP, as 
well as PS1 endoproteolysis.  
Conclusions. Taken together, we have shown that this screen can 
identify known APP metabolism regulators that control proteolysis, intracellular 
trafficking, maturation and levels of APP and its proteolytic products. We 
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demonstrate for the first time that Ubiquilin 1 regulates APP metabolism in the 
SH-SY5Y, human neuroblastoma, cell line.  
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Background 
Alzheimer’s disease (AD) is characterized by significant accumulation of 
cerebral amyloid plaques and intraneuronal neurofibrillary tangles. Amyloid 
plaques are composed mainly of the β-amyloid peptide (Aβ). Aβ is a normal 
product of amyloid precursor protein (APP) metabolism. Several genes have 
been identified encoding enzymes that directly metabolize APP to generate Aβ; 
however, it is not fully understood how APP metabolism is regulated. Here we 
describe and validate a novel experimental approach for identifying genes 
encoding regulators of APP metabolism.   
Aβ is generated by the successive proteolytic processing of APP, a process 
referred to as regulated intramembrane proteolysis (RIP) [50, 99, 100]. RIP 
occurs when a transmembrane protein is cleaved within the transmembrane 
domain, releasing a cytoplasmic fragment that can activate gene expression in 
the nucleus [99]. RIP requires two cleavage events; the first, outside the 
membrane, often in response to ligand binding, can trigger the second, 
intramembraneous, cleavage. RIP liberates small, intracellular protein domains 
that are involved in nuclear signaling processes [99, 100]. Therefore, regulation 
of RIP is critical for controlling nuclear signaling. Identifying the regulatory 
mechanisms controlling these proteolytic steps is important for a fuller 
understanding of these processes. 
APP is a type I transmembrane glycoprotein and is suggested to function in 
neuroprotection, synaptic transmission, signal transduction, and axonal 
transport [101, 102]. Upon being synthesized, APP undergoes maturation in the 
protein secretory pathway. APP is N-glycosylated in the ER and cis-Golgi 
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followed by O-glycosylation in medial- and trans-Golgi. RIP of APP can occur 
via two alternative routes: amyloidogenic and non-amyloidogenic. In 
amyloidogenic processing, APP undergoes sequential cleavage by β-secretase 
(BACE) and γ-secretase to generate Aβ [23]. BACE cleavage occurs in the 
APP extracellular domain to produce a soluble extracellular fragment called 
sAPPβ and a membrane associated, 99-residue C-terminal fragment called 
C99 [39] The C99 fragment is a substrate for subsequent cleavage by the γ-
secretase complex [51, 103]. The active γ-secretase complex is composed of 
the amino- and carboxy-terminal fragments of presenilin1 (PS1), a highly 
glycosylated form of nicastrin (NCSTN), Aph1α and Pen-2 [51, 103]. The 
amino- and carboxy –terminal fragments of PS1 (~27 and ~17 kDa 
respectively) are derived by endoproteolytic cleavage of the inactive, full length 
PS1 protein within the large hydrophilic loop that spans between 
transmembrane helices 6 and 7 and are thought to interact with each other 
[104]. The products of γ-secretase cleavage are the cytoplasmic APP 
Intracellular Domain (AICD) fragment and Aβ peptides of varying length, mainly 
40 and 42 residues long [105-107]. In non-amyloidogenic processing, the initial 
extracellular cleavage of APP is catalyzed by one of a group of proteases 
termed α-secretases. These enzymes include ADAM9, ADAM10, and ADAM17 
(TACE). α-secretase cleavage produces a soluble extracellular fragment called 
sAPPα and a membrane associated, 83-residue C-terminal fragment called 
C83. This C83 fragment is then cleaved by the γ-secretase complex to produce 
AICD and a p3 peptide, which is not involved in amyloidogenesis [23]. 
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A common feature of RIP processing is the liberation of an intracellular 
protein domain that initiates nuclear signaling [99, 100]. In the case of APP 
processing, nuclear signaling can be initiated by the production of the 
intracellular AICD fragment. Once generated by γ-secretase, the AICD 
fragment can be stabilized and transported to the nucleus by the cytoplasmic 
adaptor protein Fe65 [108, 109]. Upon entering the nucleus the AICD/Fe65 
complex can form a tripartite, transcriptionally active complex with the histone 
acetyltransferase Tip60 [66, 110]. Consistent with this model, cells 
concomitantly over-expressing an APP-Gal4-DNA binding domain fusion 
protein and Fe65, and carrying a Gal4 UAS-driven reporter construct display a 
>2000 fold increase in reporter transcription compared to cells over-expressing 
just the Gal4 DNA binding domain and Fe65 [66]. This increase in 
transactivation activity is dependent on Tip60 and can be abolished when the 
interaction between AICD and Fe65 is disrupted by mutagenesis of the AICD 
NPTY motif, the binding site for Fe65 [66]. However, these data do not rule out 
a possible effect of full-length APP in inducing nuclear signaling. Indeed, APP 
nuclear signaling can occur in the absence of γ-secretase activity and therefore 
does not require the AICD fragment [111]. The relative contribution of AICD-
mediated versus holo-APP mediated nuclear signaling is not clear at this time 
[66, 110, 111]. 
The genomic targets of AICD- or APP-mediated nuclear signaling are not 
clearly defined. APP, BACE, Tip60, GSK-3β, Mn-SOD, KAI1, NEP and other 
genes have all been reported to be targets of APP mediated transcriptional 
activation [112-115]; however, there is a paucity of confirmatory reports [111]. 
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At this time, the biological role of AICD-mediated transactivation is not clear 
[113, 116, 117]. Despite this confusion, evidence suggests that defective APP 
signaling is involved in AD pathogenesis [118-122].   
Given the centrality of APP in AD, it is crucial to identify regulators of APP 
metabolism, including, but not limited to, APP proteolysis. Regulation of APP 
metabolism can occur by numerous mechanisms, including regulation of APP 
transcription, APP translation, APP maturation, intracellular trafficking of full-
length APP and APP cleavage products, APP proteolysis, and APP 
degradation. While Komano and colleagues have used a genetic screen to 
specifically identify regulators of γ-secretase activity [123], a screen that will 
identify APP metabolism regulators that act through multiple mechanisms is 
needed.  
Here we describe a novel experimental approach to identify a variety of 
regulators of APP metabolism. We use an AICD-Gal4 mediated luciferase 
expression assay as a general reporter of APP metabolism in the human 
neuroblastoma cell lines, SH-SY5Y. To validate this assay, we utilized 
pharmacologic agents, as well as forward and reverse genetics, to modulate 
APP proteolysis, AICD trafficking and AICD transactivation. To determine if 
regulators of APP maturation and PS1 endoproteolysis also can be detected 
with this screening approach, we knocked-down Ubiquilin 1 and observed 
decreased AICD-Gal4 luciferase activity. Using Western blot analysis, we show 
that Ubiquilin 1 controls APP levels, the ratio of mature to immature APP, as 
well as presenilin1 endoproteolysis, confirming the previously reported role of 
Ubiquilin 1 in APP and presenilin1 metabolism in non-neuronal human cell lines 
[124-127]. Taken together, our results validate the use of the AICD-Gal4 
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mediated luciferase assay in combination with forward and reverse genetics as 
a screen to identify APP metabolism regulators. 
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Results 
Establishment of a functional assay to identify APP metabolism 
regulators. We utilized the APP-Gal4 / Gal4-UAS luciferase reporter system 
(Figure 1A) developed by Cao and Südhof [66]. We established this assay 
system in our laboratory by creating a SH-SY5Y, human neuroblastoma, cell 
line that stably expresses the assay components. Three different stable cell 
lines have been generated; all stably carry a luciferase reporter gene under the 
control of the Gal4-UAS (Gal4-UAS luciferase). In addition to this reporter gene, 
one cell line expresses the Gal4 DNA binding domain alone (SY5Y-Gal4), the 
second cell line expresses APP695 fused to the Gal4 DNA binding domain 
(SY5Y-APP-Gal4), and the third cell line expresses a mutated version of 
APP695-Gal4 (SY5Y-APP*-Gal4). This mutation in APP alters the NPTY motif 
(P685A; Y687A) and disrupts Fe65 binding to this site [66]. Once these cells 
were established, luciferase assays were performed to determine the relative 
luciferase activity of the cell lines (Figure 1B). SY5Y-APP-Gal4 cells have a 
statistically significant (p < 0.01) ~20 fold increase in luciferase activity 
compared to SY5Y cells expressing either Gal4 or APP*-Gal4.  
Pharmacologic modulation of α- and γ-secretase activity alters AICD-
Gal4 mediated luciferase activity. To determine if monitoring AICD-Gal4 
mediated luciferase activity is a valid method to detect alterations in APP 
metabolism, we used pharmacologic agents known to modulate APP proteolytic 
processing and compared the effects of these agents on levels of APP 
proteolytic products and AICD-Gal4 mediated luciferase activity.  To 
accomplish this, we treated our SY5Y-APP-Gal4 cells with pharmacologic 
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modulators of α-, β-, and γ-secretase activity and measured the effects using 
Western blot analyses for APP cleavage products as well as AICD-Gal4 
mediated luciferase activity.  
L-685,458 is a transition state inhibitor of γ-secretase that prevents Aβ 
and AICD generation [128]. We treated SY5Y-APP -Gal4 cells with L-685,458 
(2.5 μM for 10 hours) or with vehicle (DMSO) and collected cell lysates. We 
performed Western blot analysis on these cell lysates using an antibody to the 
C-terminus of human APP. In vehicle treated cells we observe bands migrating 
at ~28 and ~26 kDa (Figure 2A). Cao and Sudhof observed a similar doublet at 
approximately the same relative molecular weight. They identified these bands 
as C83-Gal4 and AICD-Gal4, respectively. In L-685,458 treated cells the 
intensity of the C83-Gal4 band is significantly increased seven-fold (p<0.01) 
and the AICD-Gal4 band is significantly decreased by 80% (p<0.01;Figure 2B). 
These results are consistent with the substrate / product relationship between 
C83-Gal4 and AICD-Gal4. The size difference between C83-Gal4 and AICD-
Gal4 is what is expected for γ-secretase cleavage of C83-Gal4. It is also 
interesting to note that normally AICD is difficult to detect by Western blot 
analysis, however the AICD-Gal4 fusion levels are quite high. This suggests 
that the AICD-Gal4 fusion must protect AICD-Gal4 from degradation by IDE 
and/or other proteases [129]. 
L-685,458 treatment of SY5Y-APP-Gal4 cells results in a concentration-
dependent decrease in AICD-Gal4 mediated luciferase activity; at a 
concentration of 2.5 μM there is a ~75% decrease in luciferase activity (Figure 
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2). The L-685,458 concentration required for 50% inhibition of AICD-Gal4 
mediated luciferase activity is 1.25 μM.  
The phorbol ester, PMA (phorbol 12-myristate 13-acetate), stimulates α-
secretase activity [25]. Treatment of SY5Y-APP-Gal4 cells with PMA (1 μM for 
10 hours) increased levels of the α-secretase cleavage products sAPPα and 
C83-Gal4, four-fold and two-fold, respectively (p < 0.01; Figures 2D & 2E). In 
addition, Western blot analysis revealed a two-fold increase in AICD-Gal4 
levels (p < 0.01; Figure 2D & 2E). This two-fold increase in AICD-Gal4 levels 
suggested that a similar PMA-induced increase in AICD-Gal4 mediated 
luciferase activity should be observed. Indeed, when we measured luciferase 
activity as a function of increasing PMA concentration (Figure 2F), we observed 
a dose-dependent increase in luciferase activity. The PMA-induced increases in 
luciferase activity plateaus at 50 nM PMA. At concentrations of 50 nM and 
higher, we observed approximately a two-fold increase in AICD-Gal4 mediated 
luciferase activity in close agreement with the observed two-fold increase in 
AICD-Gal4 by Western blot analysis.  
TAPI-1 (Tumor necrosis factor-α protease inhibitor 1) inhibits α-secretase 
mediated shedding of the APP ectodomain [37]. Treating the SY5Y-APP-Gal4 
cells with TAPI-1 (20 μM for two hours; Figure 2G & 2H) resulted in a modest, 
yet significant decrease of sAPPα (31%, p<0.05), C83-Gal4 (27%, p<0.01) and 
AICD-Gal4 levels (36%; p<0.01), as well as in AICD-Gal4 mediated luciferase 
activity (38%; p<0.01). In addition, TAPI-1 exhibits a dose-dependent effect 
with 20 μM resulting in a 37% decrease in AICD-Gal4 mediated luciferase 
activity (Figure 2I). Again, these data show that alterations in AICD-Gal4 levels 
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as detected by Western blot can be accurately detected by the AICD-Gal4 
mediated luciferase assay.  
Finally, we treated SY5Y-APP-Gal4 cells with a β-secretase inhibitor (β-
secretase inhibitor II). This inhibitor prevents BACE-mediated cleavage of APP 
and generation of Aβ [130]. Treating these cells resulted in no observable 
change in AICD-mediated luciferase activity. This result is not surprising given 
the very low levels of β-secretase cleaved APP (C99-Gal4) that we observe in 
these cells compared to the high levels of α-secretase cleaved APP (C83-Gal4) 
we observe (Figures 2A, 2D, 2G). We estimate that of all the APP molecules 
undergoing α- or β-secretase cleavage only about 10% are cleaved by β-
secretase, using our Western blot data (data not shown). Therefore, inhibition 
of BACE, even if effective, may result in an undetectable change in the levels of 
cleavage products in this experimental scheme.  
In summary, pharmacologic modulation of α- and γ-secretase activities 
alters AICD-Gal4 mediated luciferase activities that accurately correspond to 
the changes in AICD-Gal4 levels determined by Western blot analysis.  
     Genetic manipulation of secretase levels modulates AICD-Gal4 
mediated luciferase activity. To further validate the AICD-Gal4 mediated 
luciferase assay as a reporter of APP metabolism, we over-expressed and 
knocked-down the expression of genes involved in α-, β- & γ-secretase 
activities. Again, we compared the effects of over-expression or knock-down on 
levels of APP proteolytic products quantified by Western blot analysis to AICD-
Gal4 mediated luciferase activity in SY5Y-APP-Gal4 cells.  
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 Over-expression experiments were conducted by transiently transfecting 
individual over-expression plasmids or empty vector controls into the SY5Y-
APP-Gal4 cells. Cell lysates and conditioned media were collected 24 – 48 
hours post transfection. ADAM10 and ADAM17 over-expression promoted α-
secretase cleavage of APP and increased sAPPα secretion as compared to 
"empty vector" transfected cells (Figure 3A – 3D). ADAM10 and ADAM17 over-
expression also significantly increased C83-Gal4 and AICD-Gal4 levels as 
detected by Western blot (Figure 3A – 3D). Specifically, AICD-Gal4 levels 
increased approximately three-fold for both (Figure 3B & 3D). Measuring AICD-
Gal4 mediated luciferase activity, we found that over-expression of ADAM10 
and ADAM17 resulted in a statistically significant three to four fold increase in 
luciferase activity (Figure 3E). Furthermore, over-expression of the β-secretase 
gene (BACE) or individual components of the γ-secretase complex (PSEN1, 
PEN2, APH1, and NCSTN) or another α-secretase member ADAM9 also 
results in increased luciferase activity (Figure 3E). Specifically, BACE over-
expression significantly increased luciferase activity approximately two fold (p < 
0.01), PEN2 and NCSTN over-expression increased luciferase activity up to 
two fold (p < 0.01.)  However, over-expression of PSEN1 and APH1 did not 
result in any significant change in luciferase activity.  
We knocked-down the genes responsible for α- and γ-secretase using 
commercially available shRNAs [96]. A control shRNA, which is not 
complementary to any known human gene, was used as a negative control. 
SY5Y-APP-Gal4 cells were transfected with individual shRNAs and selected 
with 2 μg/ml puromycin for 5 to 7 days. Conditioned media and cell lysates 
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were collected from these cells and utilized for Western blot analyses and 
luciferase assays. shRNAs specific for APP, ADAM10, and ADAM17 were 
tested for their ability to knock-down their target genes (Figure 4A, 4B, 4C). 
Knock-down of these target genes was robust and we have observed 
significant protein knock-down with at least two different shRNA sequences for 
each target gene. Consistent with this knock-down of ADAM 10 and ADAM17, 
sAPPα levels were decreased significantly (Figure 4D & 4E). In addition, 
Western blot analyses showed AICD-Gal4 levels were also decreased when 
APP, ADAM10 and ADAM17 were knocked-down (Figure 4A, 4B, 4C). Knock-
down of these target genes also decreased AICD-Gal4 mediated luciferase 
activity (Figure 4F). Specifically, APP knock-down significantly decreased 
luciferase activity about 80% (p < 0.01); furthermore α-secretase (ADAM10, 
and ADAM17) knock-down significantly decreased luciferase activity 40-60% (p 
< 0.01). Individual γ-secretase components, PSEN1, Pen2, APH1, and NCSTN, 
were also knocked-down and this resulted in significant 30-50% decreases in 
luciferase activity (p < 0.01).  
Genetic manipulation of Fe65 and Tip60 levels modulates AICD-Gal4 
mediated luciferase activity. To determine if changes in AICD metabolism 
modulated AICD-Gal4 mediated luciferase activity, we over-expressed and 
knocked-down Fe65 and Tip60. Transient over-expression of Fe65 significantly 
increased luciferase activity more than two-fold (p < 0.01), while transient over-
expression of Tip60 resulted in a 30% increase in luciferase activity that was 
not significant (Figure 5A). Knock-down of Fe65 and Tip60 resulted in a 
significant 40-50% decrease in luciferase activity (Figure 5B; p < 0.01).  
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Ubiquilin 1 regulates AICD-Gal4 levels. Having shown that monitoring 
AICD-Gal4 mediated luciferase activity accurately measures changes in AICD-
Gal4 levels induced by changes in secretase activity/levels, we wanted to 
determine if this approach could detect regulators with a less direct role in APP 
proteolysis and AICD signaling. We decided to test Ubiquilin 1 because (i) the 
gene encoding Ubiquilin 1 (UBQLN1) is located in a region of chromosome 9 
that displays linkage to AD in several independent samples [131-136], (ii) a 
polymorphism in UBQLN1 modulates AD risk in several independent samples 
[137-139], (iii) Ubiquilin 1 can modulate APP trafficking to the cell surface in 
HEK-293 and H4 cell lines [124], and (iv) Ubiquilin 1 can modulate γ-secretase 
activity, though the consequences of this modulation on γ-secretase substrates 
were not determined [125-127]. Given this, testing Ubiquilin 1 would determine 
if our genetic screen can detect regulators of APP trafficking and presenilin 
endoproteolysis. Furthermore, the role of Ubiquilin 1 in APP metabolism 
regulation has not been previously investigated in SH-SY5Y cells. 
SY5Y-APP-Gal4 cells were transfected separately with five different 
Ubiquilin 1 shRNAs, APP shRNA and the control shRNA. Cell lysates were 
collected and utilized for luciferase assays. Individually, all five Ubiquilin 1 
shRNA constructs significantly decreased luciferase activity. They resulted in 
50% (p < 0.01), 60% (p < 0.01), 40% (p < 0.01), 60% (p < 0.01), and 60% (p < 
0.01) decreases in luciferase activity, respectively (Figure 6A) as compared to 
cells expressing the control shRNA. To confirm the role of Ubiquilin 1 in AICD-
mediated transcriptional activity suggested by these results, we transiently 
over-expressed Ubiquilin 1 in SY5Y-APP-Gal4 cells and measured luciferase 
activity. We observed that Ubiquilin 1 over-expression resulted in an 
 51
approximately 90% (p < 0.05) increase in luciferase activity compared to the 
empty vector control (Figure 7A).   
Ubiquilin 1 regulates APP and PS1. To begin to gain insight into the 
mechanism(s) by which Ubiquilin 1 modulates AICD-Gal4 mediated luciferase 
expression, we utilized Western blot analysis of cell lysates and conditioned 
media from SY5Y-APP-Gal4 cells in which Ubiquilin 1 was knocked-down or 
over-expressed to monitor APP and Ubiquilin 1 metabolism. Specifically, we 
analyzed cell lysates and conditioned media of cells expressing Ubiquilin 1 
shRNA number 2, since transfection with this shRNA led to the largest 
decrease in luciferase activity. Expression of this shRNA resulted in a robust 
Ubiquilin 1 knock-down and led to significantly decreased levels of mature full-
length APP, immature full-length APP, AICD-Gal4, C83-Gal4, and sAPPα 
(Figures 6B & 8). To determine if Ubiquilin 1-induced changes in APP mRNA 
levels underlie the observed changes in full length APP levels, we performed 
real-time, quantitative PCR on SY5Y-APP-Gal4 cells stably expressing either 
control or Ubiquilin 1 shRNAs. No Ubiquilin 1-induced changes in APP mRNA 
levels were observed (Figures 6C). This suggests that Ubiquilin 1 regulation of 
full-length APP levels occurs post-transcriptionally.  
We studied Ubiquilin 1 over-expression to determine if we observed the 
converse effects on APP proteolytic products and full-length APP. Indeed, we 
observed that Ubiquilin 1 over-expression resulted in increased levels of 
mature and immature full-length APP, AICD-Gal4, C83-Gal4, and sAPPα 
(Figures 7B & 8).  
The Ubiquilin 1-induced effects on full-length APP are greater on mature 
APP levels than on immature APP levels (Figure 8). This results in a decrease 
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in the ratio of mature to immature full-length APP-Gal4 when Ubiquilin 1 is 
knocked-down (p < 0.01; Figure 8) and an increase in this ratio when Ubiquilin 
1 is over-expressed (p < 0.05; Figure 8). 
Since Ubiquilin 1 has been reported to regulate PS1 endoproteolysis in 
HEK-293 cell lines, we sought to determine if the Ubiquilin 1-induced changes 
that we observed in AICD-Gal4 and C83-Gal4 levels may be due in part to 
changes in PS1 endoproteolysis  [127].  Ubiquilin 1 knock-down in SY5Y-APP-
Gal4 cells decreased PS1 carboxy-terminal fragment levels (PS1-CTF; Figure 
6D) and Ubiquilin 1 over-expression increased PS1-CTF levels (Figure 7C). We 
did not observe any changes in the levels of ADAM 10, ADAM 17 or BACE 
when Ubiquilin 1 was over-expressed or knocked-down (data not shown).   
Finally, we over-expressed Ubiquilin 1 in naïve SH-SY5Y to ensure that 
the results we observed are not limited to the SY5Y-APP-Gal4 cell line. We 
found that in these naïve cells Ubiquilin 1 over-expression resulted in increased 
total, mature and immature APP, sAPP as well as PS1 CTF, consistent with our 
findings in SY5Y-APP-Gal4 cells (data not shown). 
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Discussion 
        Taking advantage of the APP intracellular domain’s (AICD) ability to 
activate transcription, we established an assay to monitor APP metabolism in 
the human neuroblastoma cell line, SH-SY5Y. We are using this assay in 
combination with RNAi-mediated knock-down of positional candidate genes as 
a genetic screen to identify regulators of APP metabolism. Here we describe 
validation of this experimental approach using pharmacologic and genetic 
modulation of known APP metabolism regulators. We find that AICD-Gal4 
mediated luciferase activity is significantly and accurately changed when 
secretases, Fe65, Tip60, or Ubiquilin 1 levels / activities are modulated 
pharmacologically or genetically. The ability of Ubiquilin 1 to regulate APP 
metabolism in SH-SY5Y cells had not been investigated previously. Our initial 
findings show that in these cells Ubiquilin 1 regulates total APP levels, APP 
maturation and PS1 endoproteolysis. Our results lead us to conclude that the 
genetic screen we describe is capable of identifying genes that encode 
regulators of APP proteolysis, APP maturation, APP levels, and AICD activity.  
Validation of AICD-Gal4 luciferase assay. The functional assay for 
identifying APP metabolism regulators relies on the ability of an AICD-Gal4 
fusion to transactivate a firefly luciferase reporter gene [66]. While the biological 
role of AICD-mediated transactivation is unclear [113, 116, 117, 140], we 
utilized this transactivation function purely as a reporter of APP processing and 
therefore APP metabolism. We determined that monitoring AICD-Gal4 
mediated luciferase activity is correlated to AICD-Gal4 levels by utilizing 
pharmacologic and genetic agents to regulate secretase activities and thereby 
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modulate AICD-Gal4 levels. In SH-SY5Y cells stably expressing an APP-Gal4 
fusion protein and a Gal4-UAS driven luciferase reporter construct (SY5Y-APP-
Gal4 cells), we utilized TAPI-1 and L-685,458 to inhibit α- and γ-secretases 
respectively. TAPI-1 inhibits α-secretase cleavage of APP as well as several 
other cell surface proteins including TNFα [37]. L-685,458 is a potent and 
selective cell-permeable γ-secretase inhibitor [63]. Both of these inhibitors 
decreased AICD-Gal4 levels and decreased AICD-Gal4 mediated luciferase 
activity to similar levels. Inhibiting BACE activity did not have an appreciable 
effect on AICD-Gal4 levels or AICD-Gal4 mediated luciferase activity, which is 
not surprising since the majority of APP processing occurs via the α-secretase 
pathway in SH-SY5Y cells. Stimulation of α-secretase using PMA [141] 
increased AICD-Gal4 levels and increased AICD-Gal4 mediated luciferase 
activity to similar levels.  
     To further validate our functional assay, we over-expressed and knocked-
down genes that encode the α-, β-, and γ-secretases. Similar to the effects of 
pharmacologic modulators of secretases, over-expressing or knocking-down 
secretase genes resulted in predictable alterations in AICD-Gal4 levels as 
measured by Western blot analysis. The changes in luciferase activity induced 
by secretase over-expression or knock-down mirrored the trends observed in 
the Western blot analysis. Knock-down of APP had the most dramatic effect on 
AICD-Gal4 mediated luciferase activity while knock-down of genes encoding α- 
and γ-secretases resulted in significant decreases in AICD-Gal4 mediated 
luciferase.  
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To assess the quality of the AICD-Gal4 mediated luciferase assay we 
calculated the “Z-factor” for the assay in response to the known APP 
metabolism modulators[142]. The Z-factor is a dimensionless metric that takes 
assay dynamic range and data variation into consideration to assess the utility 
and reliability of the assay. Scores between 0.5 and 1.0 indicate an excellent 
assay [142]. Using the data we collected, we calculated Z-factors for 
pharmacologic and genetic modulation of the secretases (Table 2-1). For all of 
these conditions we obtain Z values between 0.5 and 1.0, indicating that our 
experimental approach is robust and has the capability of identifying APP 
metabolism regulators that increase or decrease AICD generation.   
AICD metabolism regulators modulate AICD-Gal4 luciferase activity. AICD-
Gal4 mediated transactivation has been shown to require Fe65 and Tip60.  
Fe65 is an adaptor protein that binds to the NPTY sequence in AICD and 
mediates intracellular trafficking of AICD-Gal4 from the cytoplasm into the 
nucleus [66]. Once inside the nucleus, the AICD-Gal4/Fe65 complex recruits 
the histone acetyltransferase, Tip60. Fe65 and Tip60 are both required for 
AICD-Gal4 transactivation activity. We observed increased AICD-Gal4 
mediated luciferase activity when we over-expressed Fe65 or Tip60 and 
decreased luciferase activity when either of these genes was knocked-down.   
Ubiquilin 1 modulates APP metabolism in SH-SY5Y cells. Having validated 
our experimental approach using direct regulators of APP proteolysis and 
AICD-metabolism, we then sought to determine if Ubiquilin 1 could modulate 
AICD-Gal4 mediated luciferase activity. Ubiquilin 1 has been shown to regulate 
presenilin1 endoproteolysis and APP trafficking in HEK-293 cells [124-127] and 
therefore testing Ubiquilin 1 would help to determine whether our experimental 
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approach could detect APP metabolism regulators that are not directly involved 
in APP proteolysis nor in AICD signaling. When Ubiquilin 1 was knocked-down, 
AICD-Gal4 luciferase activity was significantly decreased.  
Ubiquilin 1 is a conserved protein that contains an NH2-terminal ubiquitin-
like domain (UBL) and a COOH-terminal ubiquitin-associated (UBA) domain 
[125]. Through these domains, Ubiquilin 1 associates with ubiquitin ligases and 
the proteosome and is proposed to link ubiquitination with proteosome-
mediated protein degradation. This suggests that Ubiquilin 1 plays a role in 
responding to protein misfolding, aggregation, and/or stress [125, 143]. In the 
brains of AD patients, there is increased Ubiquilin 1 in neurons containing 
neurofibrillary tangles (NFTs), as compared to control brains [125]. In the brains 
of Parkinson’s disease patients, as well as patients with diffuse Lewy body 
disease (DLBD), there is strong Ubiquilin 1 staining of Lewy bodies [125]. 
Finally, a polymorphism in the UBQLN1 gene has been shown to increase AD 
risk in family-based and large case-control samples [137-139]. 
The role of Ubiquilin 1 in AD pathogenesis may be due to its ability to 
regulate formation of active γ-secretase complexes and/or regulate APP 
trafficking [124-127]. Monteiro and colleagues have found that Ubiquilin 1 can 
regulate full-length Presenilin1 (PS1), Presenilin2 (PS2), Nicastrin, and PEN-2 
levels as well as PS1 and PS2 endoproteolysis [125-127]. Specifically, Ubiquilin 
1 over-expression increased full-length presenilin (PS1 and PS2) levels in HeLa 
cells. In HEK-293 cells, Ubiquilin 1 over-expression decreased presenilin 
endoproteolysis while Ubiquilin 1 knock-down increased presenilin 
endoproteolysis [127]. In addition, Monteiro and colleagues show that nicastrin 
and Pen-2 levels are decreased by Ubiquilin 1 over-expression and increased 
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by Ubiquilin 1 knock-down in HEK-293. In addition to these effects on γ-
secretase components, Hiltunen and colleagues reported that Ubiquilin 1 
knock-down decreased steady-state full-length immature APP levels, increased 
trafficking of APP from intracellular compartments to the cell surface, and 
increased steady-state sAPPα levels in HEK-293 and H4 cell lines [124]. These 
effects on APP levels and secretion altered Aβ40 and Aβ42 levels. However, 
Ubiquilin 1 knock-down did not alter α-, β-, or γ-secretase levels or C83 and 
C99 levels in these cell lines.  
Here we found that in the human neuroblastoma cell line, SH-SY5Y, 
Ubiquilin 1 regulates total full-length APP, the ratio of mature to immature APP, 
as well as PS1 endoproteolysis. To arrive at these conclusions, we over-
expressed and knocked-down Ubiquilin 1 in SY5Y-APP-Gal4 cells and 
monitored APP metabolism using Western blot analysis. We found that 
Ubiquilin 1 knock-down decreased levels of AICD-Gal4, C83-Gal4, sAPPα, full-
length mature and immature APP, and the ratio of mature to immature APP. 
Ubiquilin 1 over-expression elicited the opposite effect on the levels of these 
molecules. 
The fact the ratio of mature to immature APP is altered by Ubiquilin 1 in the 
absence of APP mRNA level changes suggests that Ubiquilin 1 modulates 
trafficking through the secretory pathway in SH-SY5Y cells. This conclusion 
was reach by Hiltunen and colleagues when investigating the role of Ubiquilin 1 
on APP metabolism in H4 and HEK-293 cell lines [124].  
Given the existing reports that Ubiquilin 1 regulates PS1 levels and 
endoproteolysis in HeLa and HEK-293 cells, respectively, we sought to 
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determine if the observed changes in APP processing may be due, in part, to 
Ubiquilin 1 mediated changes in PS1 metabolism [125-127]. Interestingly, 
Hiltunen and colleagues did not observe any changes in PS1 levels or 
endoproteolysis upon transient Ubiquilin 1 knock-down in HEK-293 [124]. In 
SY5Y-APP-Gal4 cells, we observed that Ubiquilin 1 knock-down decreases 
PS1 endoproteolysis and Ubiquilin 1 over-expression promotes PS1 
endoproteolysis. Presumably these changes in PS1-CTF levels alter γ-
secretase activity and cleavage of other γ-secretase substrates. At this time, it 
is not clear how Ubiquilin 1 regulates PS1 endoproteolysis. No alterations in 
ADAM10, ADAM17, or BACE levels were observed when Ubiquilin 1 was 
knocked-down or over-expressed. These results suggest that Ubiquilin 1 
regulates APP metabolism not only by controlling the ratio of mature to 
immature APP but also by post-transcriptionally controlling total APP (mature 
and immature) levels and PS1 endoproteolysis. 
It is interesting to note that the effects of Ubiquilin 1 over-expression / 
knock-down on APP and presenilin metabolism that we observe in SH-SY5Y 
cells are different than those observed in HEK-293 and HeLa cells [124, 127]. 
In SH-SY5Y cells we find Ubiquilin 1 knock-down decreased total, mature, and 
immature full-length APP, sAPPα, C83 and AICD steady-state levels and the 
ratio of mature to immature APP, while over-expression increased these same 
steady-state levels. In addition, Ubiquilin 1 over-expression increased PS1 
endoproteolysis. In HEK-293 cells, Hiltunen et al. found that Ubiquilin 1 knock-
down decreased steady-state immature full-length APP levels, increased 
sAPPα levels, and no effects were observed in C83, C99, AICD, and PS1 CTF 
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levels [124]. However, Massey et al. observed an increase in PS1 
endoproteolysis in HEK-293 cells [127]. In SH-SY5Y cells however, Ubiquilin 1 
seemingly has opposite effects on APP and presenilin metabolism than 
observed in HEK-293. At this time the reasons for these differences are not 
clear; they could be due to differences in experimental procedure (e.g. 
differences in cell confluency, and/or RNAi techniques [transient siRNA versus 
stable shRNA]) and/or inherent differences in these two cell types. One of the 
noticeable differences between these cells is that in SH-SY5Y cells, the 
majority of full-length APP is mature, whereas in HEK-293 the majority of full-
length APP is immature (data not shown). Cell type dependent effects of 
Ubiquilin 1 have been observed previously. In COS7 cells, Ubiquilin 1 over-
expression reduced cell surface expression of nicotinic acetylcholine receptors 
(nAChRs), while in superior cervical ganglion neurons Ubiquilin 1 over-
expression had no effect on nAChR levels [144]. These cell type-dependent 
effects are interesting given the differential vulnerability observed in AD brains, 
where subsets of neocortical and hippocampal neurons preferentially 
degenerate [145]. In addition to these cell type-dependent effects, Ubiquilin 1 
has been shown to function in seemingly opposite ways. Ubiquilin 1 over-
expression has been shown to promote accumulation of some proteins [HASH-
1[146], HES-1[146], and GABAA receptor[147]] as well as to promote 
degradation of other proteins [nAChRs[144] and Hepatitis C virus RNA-
dependent RNA polymerase [NS5B][148]]. It will be important to study the role 
of Ubiquilin 1 on APP metabolism in primary neurons and in vivo to determine 
its true role in regulating APP metabolism and in AD pathogenesis.  
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Our Ubiquilin 1 results suggest that in SH-SY5Y cells, Ubiquilin 1 regulates 
APP metabolism not only by controlling the ratio of mature to immature APP but 
also by post-transcriptionally controlling total APP (mature and immature) levels 
and PS1-CTF levels.  
AICD-Gal4 luciferase assay accurately reports AICD-Gal4 levels. Finally, 
we were struck by the ability of the AICD-Gal4 mediated luciferase assay to 
accurately report AICD-Gal4 levels.  To determine the correlation between 
these two, we plotted the change in luciferase activity versus the change in 
AICD-Gal4 levels as measured by Western blot analysis. AICD-Gal4 levels 
were modulated by pharmacologic or genetic modulation of secretases and 
Ubiquilin 1. This analysis revealed a strong correlation between AICD levels 
and AICD-mediated luciferase expression (Figure 9; R = 0.90). In addition, the 
best fit line of this relationship has a slope close to 1 (m ≅ 1.3) demonstrating 
that this luciferase assay provides an accurate reporter of changes in AICD-
Gal4 levels. In addition, measuring AICD-Gal4 mediated luciferase activity 
provides a simple, quick and inexpensive means for monitoring changes in APP 
metabolism. While this approach can be successfully utilized to identify genes 
that putatively modulate AICD-Gal4 levels. Additional assays, including as 
Western blot and ELISA, will be necessary to confirm their role in APP 
metabolism regulation and gain insight into the mechanism of regulation.  
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Conclusions 
We have established and validated an AICD-Gal4 based functional 
assay in SH-SY5Y cells. Using this assay in combination with RNAi, we have 
developed a genetic screen to identify regulators of APP metabolism. This 
screen accurately, robustly, and easily measures changes in AICD-Gal4 levels. 
We demonstrate that these AICD-Gal4 levels can be altered by pharmacologic 
or genetic modulation of genes that directly regulate APP levels, AICD 
trafficking/signaling, APP maturation, and APP proteolysis. Using this approach, 
we show that Ubiquilin 1 can regulate AICD-Gal4 levels in SH-SY5Y cells. 
Ubiquilin 1 regulates AICD-Gal4 levels by modulating APP levels, the ratio of 
mature to immature APP, and PS1 endoproteolysis. Taken together, our results 
demonstrate that this genetic screen is capable of identifying APP metabolism 
regulators that can modulate the APP proteolytic processing, APP maturation, 
APP levels, and AICD trafficking/signaling.   
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Methods 
Chemicals and antibodies: Phorbol 12-myristate 13-acetate (PMA), L-
685,458, and puromycin were purchased from Sigma. TAPI-1 was purchased 
from Peptides International. β-secretase inhibitor II, N-Benzyloxycarbonyl -Val-
Leu-leucinal Z-VLL-CHO, was purchased from Calbiochem. The APP C-
terminal antibody (A8717; 1:1000) and β-actin antibody (1:10,000) were 
purchased from Sigma. The 6E10, anti-APP antibody was purchased from 
Covance and utilized for detection of sAPPα (1:1000). The BACE1 antibody 
(1:1000) was purchased from Bioscience. The ADAM10 (C-terminal) antibody 
(1:1000) was purchased from ProSci. The Ubiquilin 1 antibody (1:160) was 
purchased from Zymed. The ADAM17 antibody (1:1000) was purchased from 
Chemicon. The HRP-conjugated secondary antibodies (anti-mouse and anti-
rabbit) (1:10,000) were purchased from GE.   
Plasmids. The plasmids APP-Gal4, APP*-Gal4 and Gal4, Gal4-UAS-luciferase 
(encoding firefly luciferase) were kindly provided from Dr. Thomas Südof, and 
are described elsewhere [66]. Briefly, each of these plasmids encode only the 
DNA binding domain of Gal4. The ADAM10 over-expression plasmid was kindly 
provided by Dr. Paul Saftig. The ADAM9 and ADAM17 were provided by Dr. 
Carl Blobel. The empty vector of ADAM9, ADAM10 and ADAM17 is pcDNA3.1. 
Ubiquilin 1 over-expression plasmid, which was constructed from pCMV vector, 
was kindly provided by Dr. Mervyn J. Monteiro.        
Cells and cell culture. SH-SY5Y and naïve human embryonic kidney (HEK)-
293 cells were purchased from ATCC. These cell lines were cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 
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bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml 
streptomycin. SH-SY5Y cells that stably express APP-Gal4, APP*-Gal4, or Gal-
4, and carrying the Gal4-UAS-luciferase reporter construct were constructed by 
co-transfecting one of the Gal4 constructs, the pCDNA3.1 plasmids, along with 
the Gal4-UAS plasmid, and selecting resistant clones with 400 μg/ml G418. 
These cells were then tested for γ-secretase dependent luciferase activity. 
Clonal lines that stably express luciferase were obtained and were maintained 
with media containing 200 μl/ml G418.  
RNAi. Plasmid-based shRNA constructs were purchased from Open-
Biosystems (http://www.openbiosystems.com/). These constructs are part of 
the human retroviral shRNA library housed at the Drexel University RNAi 
Resource Center. We utilized the following target specific shRNAs: for UBQLN1 
shRNAs (Open Biosystems catalog #s: v2HS_58534, v2HS_254856, 
v2HS_254715, v2HS_255129 and v2HS_58531); for ADAM9 shRNAs 
(V2HS_17130, V2HS_17127, V2HS_17126, and V2HS_17129); for ADAM10 
shRNAs (v2HS_94294, v2HS_94297, and v2HS_94295); for ADAM17 shRNAs 
(RHS3979-9619367, RHS3979-9619368, RHS3979-9619369, and RHS3979-
9619370); for BACE1 shRNAs (V2HS_25207, V2HS_25209, V2HS_25206, 
V2HS_25205, V2HS_25210); for PSEN1 shRNAs (v2HS_89932, 
v2HS_89931); for PSEN2 shRNAs (v2HS_93093); for APH1 
shRNAs (v2HS_117094, v2HS_117096); for NCSTN shRNAs (v2HS_255892). 
As a negative control shRNA, we utilized the non-silencing shRNA from Open 
Biosystems, Inc. (RHS 1707). shRNA constructs were transfected using Arrest-
In transfection reagent (Open Biosystems, Inc.) using the conditions suggested 
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by the manufacturer. Stably expressing shRNA clones were generated by 
adding 2 μg/ml puromycin 24 hours post-transfection. Populations of resistant 
clones were detected five to seven days post-transfection.  
Western Blot Analysis. Cells were lysed in RIPA cell lysis buffer (50 mM Tris-
HCL pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1mM PMSF and 1 μg/ml 
aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin), and centrifuged at 14,000 
rpm for 15 minutes at 4○C. The resulting supernatant was transferred to a new 
micro-centrifuge tube. The protein concentration of the cell lysates was 
determined using the BCA protein assay kit (Pierce, Rockford, IL) according to 
the manufacturer’s instructions. Equal quantities of protein were loaded into the 
wells of 4-12% Bis-Tris polyacrylamide gels (Invitrogen) along with See Blue 
plus 2 protein marker (Invitrogen). Gels were run using MES running buffer and 
transferred to PVDF membrane (Immobilon PSQ, Millipore) using a semi-dry 
transfer apparatus (Owl Scientific) and NuPage transfer buffer (Invitrogen). 
PVDF membranes were blocked in TBST with 5% dry milk for at least two 
hours, washed extensively, then incubated with primary antibody for either one 
hour at room temperature or overnight at 4○C. After removing the primary 
antibody, membranes were extensively washed and incubated with either goat-
anti-rabbit-HRP or goat-anti-mouse-HRP secondary antibodies (1:10,000; GE) 
for one hour at room temperature. Membranes were washed and developed 
using West Dura Extended Duration Substrate (Pierce). The blot was visualized 
using a FluoroChem 8900 imaging system (Alpha Innotech), and signals were 
quantified using AlphaEase Fc software. To account for any differences in 
loading, target band densitometries were divided by actin densitometries 
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obtained from the same lane. These corrected densitometries were normalized 
to controls in each experiment.  
 Detection of sAPPα followed the protocol detailed in Lanni et al. and 
Bergamaschi et al. [141, 149]. Briefly, conditioned media was collected and 
48% trichloroacetic acid (TCA) was added so that the TCA final concentration 
was 15%. This mixture was incubated on ice for 30 minutes, and centrifuged at 
14,000 rpm for 20 minutes. Following this spin, the supernatant was aspirated 
and discarded. 500 μl of ice cold acetone was used to resuspend the pellet. 
This mixture was placed at -20○C for at least 30 minutes, followed by 
centrifugation at 14,000 rpm for 20 minutes. The supernatant was carefully 
aspirated and discarded. The remaining pellet was air dried for 10 minutes and 
then 20 μl of RIPA was added and this sample was utilized for Western blot 
analysis. The sAPPα bands were detected using the 6E10 (1:1000) as the 
primary antibody. 
Luciferase assays. For firefly luciferase assays, 7,500 cells were plated into 
the 96 well plates. In an experiment, each treatment was applied to a total of six 
wells. After treatments, conditioned media was aspirated and discarded. 100 μl 
GLB (Glo Lysis Buffer, Promega) was added to lyse the cells. 30 μl of each cell 
lysates was transferred to a white plate (Greiner Bio-one), and 30 μl Steady-
Glo (Promega) was added. Luciferase was measured using a Top-Count 
Scintillation Counter/Luminescence Reader (Packard, Inc.) Another 30ul of 
each cell lysates was transferred to the other white color plate, and 30 μl 20X 
SYBR Green (diluted in PBS from Invitrogen 10,000X SYBR Green) was added. 
SYBR Green fluorescence was measured after 5 minutes incubation in dark 
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using an excitation wavelength of 485 nm, and emission wavelength of 527 nm, 
and an integration time of 0.1 seconds on a Fluoroscan Ascent FL fluorescence 
plate reader (Thermo Labsystems, Inc.). The luciferase signal was normalized 
to cell number by dividing the luciferase signal by the SYBR Green reading for 
the same well. For dual luciferase assays, SH-SY5Y-APP-Gal4 cells that stably 
express firefly luciferase were co-transfected with pRL-SV40, which 
constitutively over-expresses Renilla luciferase, along with other plasmids. The 
dual luciferase assay was performed 24 – 48 hours post-transfection. The 
media was aspirated and discarded. 30 μl Dual-Glo luciferase substrate 
(Promega) was added to lyse the cells. All cell lysates were resuspended and 
transferred to a white 96 well plate (Greiner Bio-one). After 10 minutes 
incubation at room temperature, firefly luciferase was measured using a Top-
Count Scintillation Counter/Luminescence Reader (Packard, Inc.). Next, 30μl 
Stop-Glo substrate (Promega) was added to the cell lysates containing Dual-
Glo. After 10 minutes room temperature incubation, Renilla luciferase was 
measured using the same Top-Count Scintillation Counter/Luminescence 
Reader (Packard, Inc.) For normalization, the firefly luciferase signal was 
divided by the Renilla luciferase signal for the same well. In an experiment, 
each treatment was applied to a total of four wells. 
RNA Extraction and Real-time, Quantitative PCR. In triplicate, cells stably 
expressing control or Ubiquilin 1 specific shRNAs were washed twice with cold 
PBS and total RNA was isolated using the RNeasy Mini Kit (Qiagen, Inc). cDNA 
was synthesized using total RNA (3.5 μg), N6 random primers (12.5 μM) and 
SuperScript II Reverse Transcriptase (Invitrogen). cDNAs were diluted 1:30 
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using RNase-free H2O to a final concentration of 2 ng. Diluted cDNAs were 
mixed with APP or 18S primer/probe sets (Applied Biosystems, Inc.; APP 
Catalog # Hs00169098_m1; 18S Catalog # Hs99999901_s1), 2X PCR 
Universal Master Mix (Applied Biosystems, Inc.) and amplified using an ABI 
7500 Real-Time PCR System following the manufacturer’s directions. To 
determine differences in APP mRNA levels, we utilized the ΔΔCt method. 
Statistical analysis. Values in the text and figures are presented as means ± 
standard errors of at least three independent experiments. Equal variance or 
separate variance two-sample student’s t-test were used, as appropriate, to 
compare two groups. Bonferroni correction analysis was used to correct for 
multiple comparisons within a single experiment.
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Figures  
Figure 2-1 - Functional screen for regulators of APP metabolism.   
(A) Model depicting APP-Gal4 reporter system. (C) Firefly luciferase activity is 
significantly increased in SH-SY5Y cells stably expressing APP-Gal4 and Gal4-
UAS Luciferase compared to SY5Y cells stably expressing either Gal4 / Gal4-
UAS Luciferase or APP*-Gal4 / Gal4-UAS Luciferase. Luciferase activity was 
normalized to total cell number using SYBR Green.  Bars represent mean 
normalized luciferase expression (+/- std. error) of 16 independent trials for 
each cell line. ** p < 0.01; Student's t-tests with sequential Bonferroni correction 
for multiple comparisons. 
Figure 2-2 - Pharmacological modulation of secretases alters AICD-Gal4 
levels and AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4 cells.  
(A) Stimulation of α-secretase by PMA (1 μM PMA for 10 hours) increases 
sAPPα, C83-Gal4, and AICD-Gal4 levels as detected by Western blot analysis. 
(B) Quantification of Western blot densitometry in panel A. Normalization for 
loading differences was achieved by dividing the densitometry values for 
individual bands by the densitometry values for β-actin in the same lane. (C) 
Dose-dependent increases of AICD-Gal4- mediated luciferase activity with 
increasing concentrations of PMA (10 hour incubation). Luciferase levels 
normalized to total cell number using protein concentration. (D) Inhibition of α-
secretases by TAPI-1 (20 μM for two hours) results in decreases in sAPPα, 
C83-Gal4, and AICD-Gal4 levels as detected by Western blot analysis. (E) 
Quantification of Western blot densitometry in panel D. (F) Dose-dependent 
decreases in AICD-Gal4-mediated luciferase activity with increasing TAPI-
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1concentrations (two hour incubation). Luciferase levels normalized to total cell 
number using SYBR Green. (G) Inhibition of γ-secretase by L-685,458 (5mM) 
decreases AICD-Gal4 levels and increases C83-Gal4 levels as detected by 
Western blot analysis. (H) Quantification of Western blot densitometry in panel 
G. (I) Dose-dependent decreases in AICD-Gal4-mediated luciferase activity 
with increasing concentrations of L-685,458. For the luciferase experiments, 
points represent mean normalized luciferase activity (+/- standard error) of 
three independent trials, with luciferase levels normalized to total cell numbers 
using SYBR Green. ** p < 0.01; Student's t-tests with sequential Bonferroni 
correction for multiple comparisons. “Control” uses the same media as the 
treatments, and also contains the same amount of DMSO.  
Figure 2-3 - Over-expression of individual secretase genes in SY5Y-APP-
Gal4 cells increases AICD-Gal4 mediated luciferase activity.  
(A) Transient over-expression of ADAM10 increases ADAM10, AICD-Gal4, 
C83-Gal4, and sAPPα levels compared to cells transfected with empty vector. 
(B) Quantification of Western blot densitometry in panel A. (C) ADAM17 
transient over-expression significantly increases ADAM17, AICD-Gal4, C83-
Gal4, and sAPPα levels. (D) Quantification of Western blot densitometry in 
panel G. (E) Transient over-expression of individual secretase genes increases 
AICD-Gal4 mediated luciferase activity. Luciferase was normalized to 
transfection efficiency, by dividing by Renilla luciferase activity. Individual 
secretase over-expression plasmids were co-transfected with pRL-SV40 
plasmid, expressing Renilla luciferase. Bars represent the mean normalized 
luciferase activity of four independent trials and error bars represent standard 
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errors. Statistical significance was determined using two-sample, one-tail t-tests 
to compare each secretase gene with the empty vector, followed by sequential 
Bonferroni procedure to adjust for multiple comparisons. *p<0.05; ** p<0.01  
Figure 2-4 - Knock-down of APP and individual secretase genes in SY5Y-
APP-GAL4 cells decreases AICD-Gal4 mediated luciferase activity.  
(A) APP-specific shRNA decreases full-length APP, C83-Gal4, and AICD-Gal4 
levels compared to the control or “non-silencing” shRNA. Results from duplicate 
transfections with each shRNA are shown. (B) ADAM10 specific shRNAs 
decrease endogenous ADAM10, C83-Gal4, and AICD-Gal4 levels compared to 
the control shRNA. Results from duplicate transfections with each shRNA are 
shown. (C) ADAM17 specific shRNAs decrease endogenous ADAM17, C83-
Gal4, and AICD-Gal4 levels compared to the control shRNA. Results from 
duplicate transfections with each shRNA are shown. (D) Knock-down of 
ADAM9, 10, and 17 decrease sAPPα levels compared to control shRNA. (E) 
Quantification of Western blot densitometries in panels B – D. (F) Transfection 
with shRNAs specific for APP and individual secretase genes decreases AICD-
Gal4-mediated luciferase expression compared to control shRNA. Bars 
represent the mean normalized luciferase activity of four independent trials and 
error bars represent standard errors. Statistical significance was determined 
using two-sample, one tailed t-tests to compare each secretase shRNA with the 
control shRNA and sequential Bonferroni procedure to adjust for multiple 
comparisons. *p<0.05; ** p<0.01.  
Figure 2-5 - Genetic alteration of Fe65 or Tip60 levels modulates AICD-
Gal4 mediated luciferase activity. 
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(A) Transient over-expression of Tip60 or Fe65 in SY5Y-APP-Gal4 cells 
increases AICD-Gal4 production compared to empty vector controls. (B) Knock-
down of Fe65 or Tip60 in SY5Y-APP-Gal4 cells decreases AICD-Gal4 
mediated luciferase activity Bars represent the mean normalized luciferase 
activity of four independent trials and error bars represent standard errors. 
Statistical significance was determined using two-sample, one-tailed t-tests to 
compare each secretase gene and "vector" or "control" and sequential 
Bonferroni procedure to adjust for multiple comparisons. * p<0.05.  
Figure 2-6 - Ubiquilin 1 knock-down regulates APP-Gal4 metabolism in 
SY5Y-APP-Gal4 cells.  
(A) Ubiquilin 1 knock-down decreases AICD-Gal4-mediated luciferase activity. 
SY5Y-APP-Gal4 cells stably expressing the control shRNA, an APP specific 
shRNA, or five different shRNA targeting Ubiquilin 1 was generated. Cell 
lysates were utilized to measure AICD-Gal4 mediated luciferase activity. Bars 
represent the mean normalized luciferase activity (+/- standard error) of six 
independent trials. (B) SY5Y-APP-GAL4 cells stably expressing Ubiquilin 1 
specific shRNA (#2) have decreased Ubiquilin 1, mature and immature APP-
Gal4, C83-Gal4, AICD-Gal4, and sAPPα levels compared to cells expressing 
control shRNA. (C) Ubiquilin 1 knock-down does not alter APP mRNA levels 
compared to control shRNA using quantitative PCR. (D) Ubiquilin 1 knock-down 
decreases PS1-CTF levels.  
Figure 2-7 - Ubiquilin 1 over-expression regulates APP-Gal4 metabolism 
in SY5Y-APP-Gal4 cells.  
(A) Transient Ubiquilin 1 over-expression increases AICD-Gal4 mediated 
luciferase activity. SY5Y-APP-GAL4 cells were transiently co-transfected with 
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UBQLN1 over-expression plasmid and a Renilla luciferase over-expression 
plasmid (pRL-SV40). The latter was used as a transfection efficiency control to 
normalize AICD-Gal4 mediated luciferase activity. Bars represent the mean 
normalized luciferase activity (+/- standard error) of six independent trials. 
Statistical significance was determined using two-sample, one-tailed t-tests to 
compare each experimental shRNA to the control shRNA and sequential 
Bonferroni procedure to adjust for multiple comparisons. (B) SY5Y-APP-Gal4 
cells transiently over-expressing Ubiquilin 1 have increased Ubiquilin 1, mature 
and immature APP-Gal4, C83-Gal4, AICD-Gal4, and sAPPα levels compared 
to vector only cells. (C) Ubiquilin 1 over-expression increases PS1 CTF levels 
in SY5Y-APP-Gal4 cells.  
Figure 2-8 - Quantification of Western blot densitometries from Figures 6 
& 7.  
Bars represent mean densitometry (+/- standard error) of three independent 
trials. White bars represent the densitometry from Ubiquilin 1 knock-down cells; 
gray bars represent the densitometry from control cells (either control shRNA or 
empty vector for knock-down and over-expression respectively); black bars 
represent the densitometry from Ubiquilin 1 over-expressing cells. 
Abbreviations: Ma APP denotes mature APP, Im APP denotes immature APP; 
Ma/Im APP denotes the mature APP/ immature APP ratio. Statistical 
significance between mock and over-expression for each measure was 
determined using a two-sample, one tailed t-test and sequential Bonferroni 
procedure to adjust for multiple comparisons. (* p<0.05; **p<0.01.)  
Figure 2-9 - Correlation between AICD-Gal4 mediated luciferase levels and 
AICD-Gal4 levels determined by Western blot analysis.  
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(A) Using data from pharmacologic (PMA, TAPI-1, L-685,458), over-expression 
(ADAM 10, ADAM17, Ubiquilin 1) or knock-down (ADAM 10, ADAM17, 
Ubiquilin 1) mediated modulation of AICD-Gal4 levels we plotted the % change 
in AICD-Gal4 levels versus the % change in AICD-Gal4 mediated luciferase 
activity. For transient over-expression, luciferase activity and AICD-Gal4 levels 
were normalized to transfection efficiency by Renilla luciferase activity assays. 
The line is represents the linear regression to this data.  
Table 
 
Table 2-1 – Z-factor values  
Z-factor values for AICD-Gal4 Luciferase assay calculated when APP 
metabolism is modulated by pharmacologic or genetic approaches. 
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Table 2-1. Z-factor values. 
 
 
APP Metabolism Modulators Z factor 
  PMA 0.77 
Pharmacological TAPI-1 0.63 
 L685,458 0.74 
 APP 0.60 
shRNA ADAM10 0.71 
 ADAM17 0.70 
Over-expression ADAM10 0.72 
  ADAM17 0.60 
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Figure 2-1: Functional screen for regulators of APP metabolism.   
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Figure 2-2: Pharmacological modulation of secretases alters AICD-Gal4 
levels and AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4 
cells. 
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Figure 2-3: Over-expression of individual secretase genes in SY5Y-APP-
Gal4 cells increases AICD-Gal4 mediated luciferase activity.  
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Figure 2-4: Knock-down of APP and individual secretase genes in SY5Y-
APP-GAL4 cells decreases AICD-Gal4 mediated luciferase activity.  
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Figure 2-5: Genetic alteration of Fe65 or Tip60 levels modulates AICD-
Gal4 mediated luciferase activity. 
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Figure 2-6: Ubiquilin 1 knock-down regulates APP-Gal4 metabolism in 
SY5Y-APP-Gal4 cells.  
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Figure 2-7: Ubiquilin 1 over-expression regulates APP-Gal4 metabolism in 
SY5Y-APP-Gal4 cells.  
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Figure 2-8 - Quantification of Western blot densitometries from Figures 6 
& 7.  
 94
 
 
 
Figure 2-9 - Correlation between AICD-Gal4 mediated luciferase levels and 
AICD-Gal4 levels determined by Western blot analysis.  
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Figure 2- 10: APP-Gal4 fusion protein architecture. 
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ORIGIN: APP695-Gal4; total 938 amino acids  
 
 1 mlpglallll aawtvwalev ptdgnaglla epqiamfcgr lnmhmnvqng kwdsdpsgtk 
 61 tcidtkegil qycqevypel qitnvveanq pvtiqnwckr grkqckthph fvipyrclvg 
121 efvsdallvp dkckflhqer mdvcethlhw htvaketcse kstnlhdygm llpcgidkfr       
181 gvefvccpla eesdnvdsad aeeddsdvww ggadtdyadg sedkvvevae eeevaeveee      
241 eadddedded gdeveeeaee pyeeatertt siattttttt esveevvrvp ttaastpdav 
301 etpgde nehahfqkak erleakhrer msqvmrewee aerqaknlpk adkkaviqhf    
361 qekvesleqe aanerqqlve thmarveaml ndrrrlalen yitalqavpp rprhvfnmlk 
421 kyvraeqkdr qhtlkhfehv rmvdpkkaaq irsqvmthlr viyermnqsl sllynvpava 
481 eeiqdevdel lqkeqnysdd vlanmisepr isygndalmp sltetkttve llpvngefsl 
541 ddlqpwhsfg adsvpanten evepvdarpa adrglttrpg sgltniktee isevkmdaef 
601 rhdsgyevhh qklvffaedv gsnkgaiigl mvggvviatv ivitlvmlkk kplassr mkl 
661 lssieqa cdicrlkklk cskekpkcak clknnwecry spktkrsplt rahltevesr ler 
721 leqlfll ifpredldmi lkmdslqdik alltglfvqd nvnkdavtdr lasvetdmpl tlr 
861 qhrisat ssseessnkg qrqltvs pefpgippgqytsihhgv vevdaavtpe erhlskmq 
921 qn gyenptykff eqmqn 
  
 
Figure 2-11: APP-Gal4 fusion protein amino acids sequence. Regular 
characters are APP695 sequence; bold and italic characters are linker sequence; 
underlined characters are from Gal4 sequence. APP695-Gal4 contains total of 
938 amino acids. 
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Figure 2-12: Screening of APP metabolism regulator using an AICD-
mediated functional assay. 
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Figure 2-13: 11 genes were identified as APP metabolism regulators using 
our validated AICD-mediated functional assay. 
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Table 2-2: List of genes that their encoded proteins down-regulation 
decreases AICD-medicated luciferase and are considered positive APP 
metabolism regulators.  
CTSL: Cathepsin 
L 
Potential contribution of the lysosomal compartment in 
the processing of amyloid precursor protein (APP) to 
amyloid beta-peptides 
CTSL2: 
Cathepsin L2 
A cysteineprotease; proteolysis and peptidolysis; 
cathepsin L activity.  
FRMD3: FERM 
domain 
containing 3  
A multifunctional protein essential for maintaining 
erythrocyte shape and membrane mechanical 
properties.  
NTRK2: 
Neurotrophic 
tyrosine kinase, 
receptor, type 2 
Receptor for brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 and neurotrophin-4/5; involved in the 
development and/or maintenance of the nervous 
system. Indicated to be an AD suspitible gene.   
UBQLN1: 
Ubiquilin 1 
In vivo protein degradation, modulates accumulation of 
presenilin proteins, and is found in lesions associated 
with Alzheimer's and Parkinson's disease.  
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KIF27: kinesin family 
member 27 Kinesin motor 
NINJ1: Ninijurin1  
Homophilic cell adhesion molecule that promotes 
axonal growth. May play a role in nerve regeneration 
and in the formation and function of other tissues; 
neurogenesis  
NR4A3: nuclear 
receptor subfamily 
4, group A, member 
3 
Neuron-derived orphan receptor; Mitogen-induced 
nuclear orphan receptor 
PPP3R2: Protein 
phosphatase 3 
(formerly 2B), 
regulatory subunit B, 
beta isoform  
Regulatory subunit of calcineurin, a calcium-
dependent, calmodulin stimulated protein 
phosphatase. calcium ion binding; MAPK signaling 
pathway; Apoptosis; Long term memory 
SPTLC1: serine 
palmitoyltransferase, 
long chain base 
subunit 1  
Catalytic activity: Palmitoyl-CoA + L-serine = CoA + 
3-dehydro-D- sphinganine + CO(2). Belongs to the 
class-II pyridoxal-phosphate-dependent 
aminotransferase family. 
SHC3: Src 
homology 2 domain-
containing 
transforming protein 
C3  
Signaling adapter that couples activated growth 
factor receptors to signaling pathway in neurons. 
signal transduction pathways of neurotrophin-
activated Trk receptors in cortical  neurons 
TMOD1: 
Tropomodulin 1 
Tropomodulin is highly concentrated at the 
postsynaptic domain of human and rat 
neuromuscular junctions; tropomyosin binding; 
cytoskeleton; organization and biogenesis; actin 
binding  
 
Table 2-3: List of genes that their encoding proteins down-regulation increases 
AICD-medicated luciferase and are considered negative APP metabolism 
regulators. 
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CHAPTER 3  
Functional characterization of APP metabolism 
Regulators  
 
CHAPTER 3.1 
 Ubiquilin 1 and protein quality control system 
 
Can Zhanga, Aleister J. Saundersa,b 
 
c- Department of Bioscience & Biotechnology, Drexel University, Philadelphia, PA  
d- Department of Biochemistry & Molecular Biology, Drexel University College of 
Medicine, Philadelphia, PA 
 
          Abstract: The refolding and degrading misfolded proteins are the 
most important function of protein quality control (PQC) system. PQC 
essential activities occur in the endoplasmic reticulum (ER), ubiquitin-
proteasome system (UPS) and lysosome. Imbalance between the 
capability of PQC system and the quantity and severity of misfolded 
proteins may cause protein aggregate to accumulate and may ultimately 
contribute to a class of diseases referred to as conformational disorders. 
Numerous lines of evidence suggest that Ubiquilin 1 is an important 
component in PQC. Ubiquilin 1 has been indicated to be involved in the 
pathophysiology of neurodegenerative diseases and cancer. A number of 
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Ubiquilin 1 interacting proteins have been identified and it seems that 
Ubiquilin 1 functions are not exclusively limited to what is classically 
defined as PQC functions. These results also implicated that Ubiquilin 1 
is important in the transcription and translation.  
 
           Introduction  
Soluble and transmembrane proteins undergo complex and precise folding 
to ensure they are in the physiologically correct conformation. The system that 
ensures correct folding is called protein quality control (PQC) system. The most 
important intracellular compartments that harbor PQC activities are endoplasmic 
reticulum (ER), ubiquitin-proteasome system (UPS) and lysosome[150-153]. In 
the normal physiological state in eukaryotes, as many as 30% newly synthesized 
proteins are indicated to undergo degradation within minutes of synthesis[151, 
154], which implies that these degraded proteins could be misfolded[155]. 
Misfolded proteins could first be recognized by the ER and retrotranslocated into 
the cytosol, or utiquitinated and degraded by the proteasome system or 
degraded by the lysosome[152]. Protein chaperones, e.g.  Hsp70, Hsp90, Hsp40, 
and Hsp104, reside in every major cellular compartment and can facilitate PQC 
functions and specifically refold or degrade misfolded proteins[156, 157]. 
Imbalance between the capability of PQC system and the quantity and 
severity of misfolded protein may cause protein aggregate to accumulate. The 
proteins that can not be degraded tend to have more severe intracellular toxicity. 
The intracellular organelle that contains such proteins is called aggresome or 
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inclusion body[158-160], which is considered a temporary protective mechanism 
to confine toxicity[161]. The rapid dividing cells can relieve the toxicity by passing 
onto daughter cells, however, the non-dividing neuron is more susceptible to 
protein aggregates[153]. Therefore, disorders of protein folding and degradation 
are emerging as a fundamental mechanism for many diseases, especially 
neurodegenerative diseases [162] . The proteins that deliver misfoled proteins to 
the proteasome include, at least in some cases, the chaperone protein 
CDC48/p97[163, 164], and a recently identified protein, Ubiquilin 1. It appears 
that Ubiquilin 1(in human), or Dsk2p (in yeast), fulfill these responsibilities, as 
well as carry out other biological functions. In this review, we summarize the 
current findings of Ubiquilin 1 inside and outside of PQC system, and we will 
discuss some clinical disorders derived from the alteration of Ubiquilin 1.  
 ER, UPS and autophagy-lysosome system 
           The ER is the most important eukaryotic organelle for protein folding and 
degradation. It contains a highly active folding machinery to fold the proteins from 
an unfolded state to their native state and enter the secretory pathway. The ER 
also recognizes misfolded proteins through the unfolded protein response (UPR) 
and targets them for elimination by a mechanism called ERAD or  ERQD ( ER-
associated quality control and degradation) [156, 165]. The misfolded proteins 
recognized by the ERQD will be degraded through the ubiquitin-proteasome 
system (UPS) or lysosome.  
             The UPS system is essential for many cellular processes, including the 
cell cycle, the regulation of gene expression, and responses to oxidative stress.  
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In the UPS, misfolded proteins are first covalently labeled with ubiquitin, a small 
conserved protein, through the process of ubiquitination or ubiquitinylation. It is 
an ATP-dependent process that involves the action of at least three enzymes: a 
ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a 
ubiquitin ligase (E3), which work sequentially in a cascade[151, 152]. 
Ubiquitinylation is an important regulatory tool that controls the concentration of 
key signaling proteins, such as those involved in cell cycle control, as well as 
removing misfolded, damaged or mutant proteins that could be harmful to the cell. 
Several clinical syndromes are caused by disruption of the genes that encode 
enzymes for ubiquitinylation, for instance, Angelman syndrome (caused by 
mutation from the gene UBE3A which encodes the protein ubiquitin protein ligase 
E3A; or larger deletion of chromosome 15 regions) and Von Hippel-Lindau (VHL) 
syndrome (caused by mutations of the VHL tumor suppressor (VHL) gene which 
encodes the VHL protein). Abnormal ubiquitinylation of proteins could results in 
intracellular accumulations, which are called inclusion bodies or aggresomes, as 
were mentioned previously. Examples of such inclusions bodies include 
neurofibrillary tangles (Alzheimer’s disease), Lewy body (Parkinson’s disease), 
Pick bodies (Pick’s disease) and Mallory’s Hyalin (alcoholic liver disease).   
After a polyubiquitinated chain is formed, the proteins will be delivered to 
the proteasome specifically for degradation (Figure 1). Structurally speaking the 
proteasome is a large barrel-like complex about 2000 kDa in molecular mass 
which contains a "core" of four stacked rings around a central pore and two 
regulatory caps on both ends. The core is where proteins are degraded and the 
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regulatory subunit contains multiple ATPase active sites and ubiquitin binding 
sites. The most common form of the proteasome is known as the 26S 
proteasome containing one 20S core and two 19S regulatory caps. The 
alternative forms of the proteasome can be the 20S core with two 11S regulatory 
caps or with two mixed caps (one 19S on one cap and one 11S of the other cap).        
Larger misfolded proteins or organelle will be degraded by the lysosome 
through hydrolytic reactions in its acidic environment. The function of its 
degrading intracellular components is called autophagy, which is different from its 
function of degrading exterior materials, or heterophagy (e.g. exterior antigens 
are presented through heterophagy) (Figure 1). In general lysosome degrades 
protein with much less specificity than the UPS. However, during a process 
called chaperone medicated autophagy (CMA), chaperones (particularly heat-
shock proteins) selectively bind and transport substrate proteins with the 
sequence of KFERQ to lysosomal receptor (LAMP-2A) and proteins are 
endocytosed into the lysosome. Disorder of autophagy can result in intracellular 
protein aggregates and lead to several neurodegenerative diseases, including 
Alzheimer’s disease (AD), Pakinsen’s disease (PD), and polyglutamine 
diseases[153].  
           
 106
             
Figure 3-1A Protein quality control systems in mammalian cells. 
Proteins degraded through ubiquitin-proteaseom system (UPS) or lysosome 
system, the two essential components of protein quality control (PQC). Proteins 
are delivered to lysosomes from the extracellular media (heterophagy) or from 
inside the cell (autophagy). Mammalian cells carry out three different types of 
autophagy: macroautophagy, microautophagy, and chaperone-mediated 
autophagy (CMA). Reproduced from the Lancet Neurology, 6 (4), Pages 352-361 
(2007) 
Ubiquilin family of proteins  
The human genome encodes four structurally related proteins: Ubiquilin 1, 
2, 3 and 4. Their encoding genes are located on different chromosome regions, 
and contain different length of amino acids. The Ubiquilin 1 gene is located on 
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chromosome 9q22, and it can encode two isoforms containing either 589 amino 
acids or 561 amino acids. The Ubiquilin-2 gene is located on chromosome Xp11 
and it encodes a protein of 624 amino acids. The Ubiquilin-3 gene is located on 
chromosome 11p15, and it encodes a protein of 655 amino acids. Ubiquilin-4 is 
located on chromosome 1q21, and it encodes a protein of 601 amino acids[166]. 
All the Ubiquilin family proteins are cytosolic proteins with different expression 
patterns. Ubiquilin 1 is expressed ubiquitously and it can be phosphorylated [167], 
Ubiquilin-2 and 4 are expressed more tissue specifically than Ubiquilin 1, and 
Ubiquilin-3 is expressed only in the testis. The four proteins differ from each other 
primarily by the presence or absence of long insertions in the middle of the 
sequence. Ubiquilin 1 is also known as PLIC1, CHAP1, DA41, DSK2(yeast), 
FLJ90054, and XDRP1(frog) [125] . Ubiquilin2 is also known as CHAP1, DSK2, 
HRIHFB2157, LIC-2, N4BP4, PLIC2, and RIHFB2157.   
Ubiquilin proteins are structurally conserved protein and contain an 
ubiquitin-like domain (UBL) in its N-terminus and an ubiquitin-associated domain 
(UBA) in its C-terminus. Functionally Ubiquilin 1 interacts with many cytosolic or 
transmembrane proteins using its functional domains and modulates their 
stability and/or steady state levels. Ubiquilin 1 can form dimmers, though the 
monomer is indicated to be involved in binding one category of its substrate, 
presenilins [168]. The rest of this review will delineate the Ubiquilin 1 involvement 
in the protein intracellular quality control system, as well as explore Ubiquilin 1 
involvement in various disorders.  
Ubiquilin 1 and protein intracellular quality control systems 
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          1. Ubiquilin 1 and ER Yeast has been used to study the proteins that are 
required for ERQD due to the ease of genetic and molecular manipulation. The 
Ubiquilin 1 homologue in yeast, Dsk2p, has been implicated in the ERQD [155, 
169] [170]. The results from these studies suggested that Dsk2p, as well as two 
other proteins, Rad23p and Cdc48, form a trimeric complex and function to 
deliver ubiquitinated proteins to the proteasome. This complex prevents 
misfolded protein aggregates from developing in the cytoplasm [170].   
2. Ubiquilin 1 and lysosome Autophagy activities have been shown to be 
regulated[153], therefore, enhancing the autophagy activities could be a 
therapeutic for the autophagy associated disorders. Rapamycin (also named as 
sirolimus or INN) was first discovered as a product of the bacterium 
Streptomyces hygroscopicus and was originally developed as an antifungal 
agent, and now used as agents of anti-rejection. Recently it was found that 
rapamycin is pro-autophagic. It can activate the functions of autophagy and 
increase the clearance of aggregated proteins in polyglutamine mutant model 
cells by inhibiting mTOR (mammalian target of rapamycin)  [171]. mTOR is 
known to control cell cycle progression and cell growth through regulation of 
translation, transcription, membrane traffic and protein degradation. It is reported 
that Ubiquilin 1 interacts directly with mTOR protein kinase [172]. Therefore it is 
implicated that autophagy activity could be regulated by Ubiquilin 1 via its 
interaction with mTOR.  
3. Ubiquilin 1 and its protein transportation properties A large amount 
of evidence shows that Ubiquilin 1 functions as an adaptor protein and links the 
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ubiquitination machinery to the proteasome to affect protein degradation [173]. 
Specifically Ubiquilin 1 mediates degradation of protein-disulfide isomerase (or 
PDI; a stress-responsible gene)[174], [175], neuronal nicotinic acetylcholine 
receptors[144] and presenilins (γ-secretase component; involved in APP 
proteolytic cleavage). It appears that Ubiquilin 1 can also enhance the 
polyubiquitination of NS5B (a crucial protein involved in HCV RNA transcription) 
[148]. If misfolded proteins exceed the degradation capacity of proteasome, 
Ubiquilin 1 can also target certain proteins to form aggresome with unidentified 
mechanism. Such examples include ataxin 3 (a deubiquitinating enzyme ), 
HSJ1a (a co-chaperone), and EPS15 (epidermal growth factor substrate 15; an 
endocytic protein)[173] [143].  
Other Ubiquilin 1 binding proteins  
Ubiquilin 1 has been found to interact directly with several other proteins 
that play various functions. Currently there is no direct evidence showing the 
Ubiquilin 1 can enhance polyubiquitination or deliver these proteins to the 
proteasome. These proteins include Eps15 and Eps15R (key components of the 
clathrin-mediated endocytic pathway) [176], mTOR (regulating cell cycling and 
cell growth through regulation of translation, transcription, membrane traffic and 
protein degradation) [172], gamma-aminobutyric acid A (GABA(A)) receptors 
(modulating efficacy of inhibitory neurotransmission) [147], human achaete-scute 
homologue-1(HASH-1; essential for development of olfactory and most 
peripheral autonomic neurons) [146], CXCR-4-βγ (a G-protein coupled receptor –
βγ units, receptor for stromal cell-derived factor1, or SDF-1, also named as 
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CXCL12 which is involved in angiogenesis), CD47 (modulator of integrin function 
and cell migration) [177].  Interestingly it has been indicated that Ubiquilin 1 
functions on SDF-1 are independent on the proteasome[177].  
            Ubiqulin 1, protein quality control and diseases 
 1. Ubiquilin 1 and Alzheimer’s disease AD is a progressive and 
degenerative disorder clinically characterized by progressive dementia that 
inevitably leads to incapacitation and death. AD pathology is characterized by the 
presence of intraneuronal fibrillary tangles and extracellular senile plaques. 
Tangles are mainly composed of microtubule associated protein tau in its 
hyperphosphoralation form. Plaques are primarily composed of the 4 kDa, 39–43 
amino acids Aβ and The Aβ peptide is generated from a transmembrane protein 
β-amyloid precursor protein (APP)[14]. Abundant genetic, cell biological and 
biochemical evidence supports the amyloid cascade hypothesis which states that 
accumulation and aggregation of Aβ is the primary cause of AD, inducing an 
inflammatory response followed by neuritic injury, hyperphosphorylation of tau 
protein and formation of fibrillary tangles, leading ultimately to neuronal 
dysfunction and cell death[1, 16, 178, 179].  
Four genes have been confirmed to be involved in AD, including APP, 
PSEN1, PSEN2, and ApoE[16, 75, 180]. Numerous genes have been suggested 
to be involved in AD pathophysiology and their functions and underlying 
mechanisms need to be confirmed. Evidence shows that Ubiquilin 1 is involved in 
neurodegenerative diseases, including AD, PD, and HD. First on the genetic 
level, Bertram et al reported that a UBQLN1 polymorphism substantially 
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increases the risk of AD, possibly by influencing alternative splicing of this gene 
in the brain [137, 181]. Second, on the immunohistochemistry level using anti-
Ubiquilin antibodies robustly stained neurofibrillary tangles and Lewy bodies in 
AD and PD affected brains, respectively[125]. Third, functionally, Ubiquilin 1 
regulates γ-secretase (the APP cleavage proteases which can produce Aβ) 
activity by regulating endoproteolysis of the presenilin 1 protein within the  γ-
secretase complex [125, 127, 182]. Fourth on the imaging level, using 
fluorescence lifetime imaging microscope, the interaction between Ubiquilin 1 
and presenilin1 was detected near the cell surface in primary neurons in vitro as 
well as in brain tissue of healthy controls and AD patients [183]. Massey et al 
reported Ubiquilin 1 and PS proteins co-localized in vesicular-like structure or 
ER- like pattern [125, 127]. Ubiquilin 1 affects APP trafficking and processing, 
thereby influencing the generation of Aβ [124].Taken together, Ubiquilin 1 is 
involved in the AD pathophysiology and may be also involved in the 
pathogenesis. It is an important modulator of presenilin protein accumulation and 
APP trafficking.  
2. Ubiqulin and polyglutamine diseases Polyglutamine (PolyQ) diseases are a 
category of neurodegenerative diseases characterized by expanded polyQ tracts. 
Based on clinical features PolyQ diseases are classified of nine different types, 
e.g. Huntington’s disease (HD) and spinocerebellar ataxia type1 (SCA1). 
However they seem to share the same underlying mechanisms which are the 
expansion of a CAG trinucleotide repeat and the breakdown of the PQC 
system[184]. Protein aggregation and cytotoxicity are observed in polyQ 
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disorders. Recent evidence suggested that Ubiquilin family proteins are involved 
in the pathophysiology of PolyQ diseases. SCA1 (previously also known as 
olivopontocerebellar atrophy type 1) is a genetic disorder clinically characterized 
by slowly progressive incoordination of gait and often associated with poor 
coordination of hands, speech, and eye movements. The disease causing gene 
Ataxin-1 (or ATX1, SCA1), is located on the chromosome 6p23 and encodes a 
protein called Ataxin-1[185], which is shown to interact with Ubiquilin-4 ( or 
ataxin-1-interacting proteins; A1UP) [186]. The mechanism of the interaction is 
still unidentified. HD is another genetic disorder characterized by mutations from 
the Huntingtin (Htt) gene located on the chromosome 4p16. Mutant Huntingtin 
protein (mHtt) forms nuclear inclusions and neuropil aggregates and results in 
neuronal cell death in select areas of the brain, which causes abnormal body 
movements called chorea and lack of coordination. Wang et al reported that 
Ubiquilin 1 suppresses polyQ-induced protein aggregation and toxicity in cells 
and in an animal model of HD [187]. 
 3. Ubiquilin 1 and cancer Cancer is characterized by uncontrolled 
division of cells.  Cyclins and cyclin-dependent kinases (CDKs) are the two 
critical classes of molecules in regulation of cell cycle progression. Funakoshi 
reported that in Xenopus cells, XDRP1, the Ubiquilin 1 homologue, bound to both 
embryonic and somatic forms of cyclin A (A1 and A2) in Xenopus cells and 
blocked embryonic cell division [188]. Ubiquilin 1 (named as DA41 in this report) 
can interact with tumor-suppressor DAN protein and S (1-5) protein, which can 
modulate DNA synthesis, thus can regulate cell growth [189]. A recent report 
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showed that Ubiquilin 1 is involved in cancer pathophysiology. Ubiquilin 1 mRNA 
and protein levels are both significantly increased, and the phosphorylated form 
is significantly reduced in lung adenocarcinoma [167] . Taken together, Ubiquilin 
1 is involved in cancer pathophysiology and possibly cancer pathogenesis.   
            Conclusion 
            In summary, the protein control system is a complex intracellular system 
which refolds and degrades misfolded cytosolic and transmembrane proteins. 
The main components in the PQC include ER, UPS and lysosome. First stages 
of PQC occur in the ER where refolding of misfolded proteins occurs through 
heat shock proteins and other chaperone proteins. UPS and lysosome seem to 
be the second stage of quality control. The proteins which can not be repaired in 
the ER will undergo UPS or lysosome. To maintain normal cellular functions, 
these three systems need to coordinate their functions. Ubiquilin 1 is a key 
adaptor protein that seems to be involved in ER, UPS and lysosome functions. 
Ubiquilin 1 binds a larger amount of proteins that function differently. It seems 
that Ubiquilin 1 can function independently of the proteasome. Imbalance of the 
PQC system will lead to misfolded proteins aggregation, and ultimately lead to 
apoptosis or cell death. Malfunctioning of PQC is an emerging mechanism for 
many disorders, including neurodegeneraton diseases and cancer. Modulation of 
Ubiquilin 1 activity may open up novel avenues for the intervention of these 
disorders.  
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Introduction 
        Alzheimer’s disease (AD) is pathologically characterized by accumulation 
of neuronal amyloid plaques and fibrillary tangles, which ultimately lead to 
neuronal death and dementia. The main components of the amyloid plaques 
are beta-amyloid peptides (or Aβ), which are 37-43 amino acid long and 
generated by the proteolytic processing of a type I transmembrane glycoprotein, 
amyloid-precursor protein (APP)[1, 14]. APP is present on almost every 
membrane containing intracellular compartments. The process that APP is 
transported onto the membrane surface after translation is called APP 
trafficking. Amyloidogenesis of APP requires two proteolytic steps involving the 
β-secretase (BACE) and γ-secretase. BACE is also a type-1 transmembrane 
protein. γ-Secretase is a membrane protein complex which contains presenilin1 
(PS1), nicastrin (NCSTN), Aph1α, Pen-2 and CD147. γ-Secretase cleavage 
can yield different length of Aβ species, among which Aβ40 and Aβ42 are the 
two main components. More Aβ42 can be found in the amyloid plaques. APP 
can also be cleaved by α-secretase, which cleaved within the Aβ sequence and 
preclude the process of amyloidgenesis. Accumulative evidences indicate that 
Aβ is the primary cause of the neuronal death for most of AD cases, though the 
underlying mechanism is not completely identified [23]. Characterizing how 
APP and Aβ metabolism is altered in the AD pathogenesis will help elucidate 
the underlying mechanism of AD.  
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          Recently a polymorphism of Ubiquilin 1 has been shown to increase the 
risk of AD in family-based and large case-control samples[137] [138, 181]. 
Ubiquilin1 has been implicated to be involved in the pathological process of 
Alzheimer’s disease, Parkinson’s disease and cancers[125, 167, 187].Ubiquilin1 
gene is located on chromosome 9q22, and it can encode two isoforms of protein 
that contains 589 amino acids (isoform1) or 561 amino acid (isoform2). Ubiquilin 
1 contains a UBL (ubiquitin-like) domain and a UBA (ubiquitin-associated) 
domain. Utilizing these functional domains, Ubiquilin1 interacts with more than 10 
intracellular or surface proteins and modulate their stability and/or steady state 
levels[125, 143, 144, 147, 172, 174-177]. Ubaln1 has also been reported to be 
involved in the protein intracellular quality control utilizing including ER and 
ubiquitin-proteasome system (UPS)[125, 170, 175, 190]. Ubiquilin 1 appears to 
be an adaptor protein, which binds polyubiquitinated proteins with its UBL or UBA 
domain and transport them to the proteasome for degradation, thus preventing 
aggregates of misfolded protein in the cytoplasm [173], [170, 190]. It is postulated 
that Ubiquilin 1 functions could also be independent on the UPS[177].  In this 
case, blocking proteasome functions using MG132 or other proteasome inhibitors 
could not inhibit Ubiquilin 1 influences on the target proteins. Ubiquilin 1 plays a 
pivotal role in the APP metabolism. First, it is demonstrated that Ubiquilin 1 alters 
APP steady state levels on a post-transcriptional level by altering APP trafficking  
pathway [124]. Secondly, Ubiquilin 1 can regulate PS1 endoproteolysis [127]. We 
have shown that Ubiquilin 1 modulates APP metabolism and PS1 
endoproteolysis in a cell type specific manner. Here we study the effect of 
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Ubiquilin 1 on APP metabolism in SH-SY5Y cells and determine if these 
functions are dependent on UPS.  
         Since apoptosis plays a critical role in the development of AD[191] and 
Ubiquilin 1 could alleviate the hypoxia induced apoptosis in SH-SY5Y cells[175], 
we also investigated the role of Ubiquilin 1 role of apoptosis.  
          In this paper we functionally characterize the Ubiquilin 1 role on APP 
metabolism in SH-SY5Y cells, followed by the study of the Ubiquilin 1 influence 
on caspase-3 activity, as well as one of caspase-3’s substrates, PARP. We find 
that Ubiquilin 1 alters APP trafficking to the cell surface without altering its half life. 
We also show that Ubiquilin 1 effects on APP metabolism are dependent on 
proteasome system. Ubiquilin 1 alters caspase-3 activity and PARP protein levels 
under stress. Next we demonstrate that Ubiquilin 1 undergoes proteasome and 
lysome degradation. Finally we find that γ-secretase inhibition can elevate 
Ubiquilin 1 steady state levels, which suggests for the first time that there exists a 
regulatory circuit modulating the Ubiquilin 1 and PS1 activities.  
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Methods 
        Chemical and antibodies: L-685,458 and puromycin were purchased from 
Sigma.  The Sulfo-NHS-LC-biotin and the streptavidin beads were from Pierce. 
β-Actin antibody  (1:10,000)  was  purchased  from  Sigma. The APP C-terminal 
antibody (A8717; 1:1000) was either purchased from Sigma or received as a 
generous gift from Dr. Sam Gandy. The Ubiquilin 1 antibody (1:160) was 
purchased from Zymed. The PARP antibody (#9542; 1:1000) was from Cell 
Signaling Technology.The HRP-conjugated secondary antibodies (anti-mouse 
and anti-rabbit) (1:10,000) were purchased from GE.   
        Plasmids:  The plasmids APP-Gal4, Gal4-UAS-luciferase (encoding firefly 
luciferase) were kindly provided from Dr. Thomas Südof, and are described 
elsewhere [16]. Ubiquilin  1  over-expression  plasmid, which  was  constructed  
from  pCMV  vector,  was  kindly  provided  by  Dr.  Mervyn J. Monteiro. 
        Cell culture: SH-SY5Y and HEK-293 cells were purchased from the 
American Type Culture Collection (ATCC). These  cell  lines  were  cultured  in  
Dulbecco's  modified Eagle's medium (DMEM) supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml 
streptomycin. SH-SY5Y cells that stably express APP-Gal4 and the Gal4-UAS-
luciferase reporter construct (named as “SY5Y-APP-Gal4 cells“) were described 
else where[182]. These cells were maintained with media containing 200 μg/ml 
G418. SY5Y-APP-Gal4 cells were transfected with non-silencing shRNA 
construct (not targeting any known genes or “control”) or shUbqln1 construct 
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(targeting Ubiquilin 1 mRNA or “shUBQLN1”). The multiple clonal cells that 
contain puromycin resistant constructs were selected and continued to grow in 
1ug/ml puromycin and 200ug/ml G418 containing media. When cells reach 15 
splitting times, they were replaced with fresh batches. 
        RNAi and stable cell line selection: Plasmid-based shRNA constructs 
were purchased from Open-Biosystems, Inc (Birmingham, AL).  These constructs 
are part of the human retroviral shRNA library housed at the Drexel University 
RNAi Resource Center. SY5Y-APP-Gal4 cells that stably express shRNA 
constructs of nonsilencing shRNA construct (Open Biosystems catalong #: RHS 
1707) and Ubiquilin 1 (Open Biosystems catalog #: v2HS_254856) were 
described else where [182]. They are described as “SY5Y-APP-Gal4-
shUbqln1”( or simply named as “shUbqln1” in certain context) or “SY5Y-APP-
Gal4-Control”(or simply named as “Control in certain context) To construct these 
stably cell lines, in brief, shRNA constructs were transfected using Arrest-In 
transfection reagent (Open  Biosystems,  Inc.), following by selection of stably 
expressing shRNA clones by adding 2 μg/ml puromycin 24 hours 
posttransfection. Populations of resistant clones were five to seven days 
posttransfection. Clones that achieved more than 50% endogenous protein 
knockdown were grown up and frozen down in liquid nitrogen. These stably cell 
lines were maintained with media containing 1ug/ml puromycin and 200ug/ml 
G418. Ubiquilin1 protein knock-down level was confirmed for every series of 
experiments. Cells were replaced with fresh batches after 15 splitting times.  
        Luciferase assay: Luciferase assay has been described previously else 
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where [182]. Briefly the firefly luciferase assays were carried out in the 96 well 
plate formats. 7,500 cells were seeded into each well. After treatments, 
conditioned media was aspirated and discarded.  100 μl Glo Lysis Buffer (GLB, 
Promega) was added to lyse the cells. For each sample, 30 μl lysate was utilized 
for firefly luciferase reading, and another 30ul lysate was utilized for SYBR Green 
reading (Invitrogen). The individual luciferase signal was further divided by by the 
SYBR Green reading for the same well for normalization.  
       Western blotting analysis: Western blotting analysis was carried out by the 
method described previously [124, 182]. Briefly cells were  lysed  in the 
radioimmunoprecipitation (RIPA) cell  lysis buffer (50 mM Tris-HCL pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% NP-40, 1mM PMSF and 1 μg/ml aprotinin, 1 μg/ml 
leupeptin, and 1 μg/ml pepstatin). After centrifugation and protein concentration 
measurement, equal amount of protein was applied to electrophoresis followed 
by membrane transfer, antibody incubation and signal development.  
       APP synthesis rate analysis: APP synthesis rate analysis has been 
described elsewhere previously [124]. SY5Y-APP-Gal4 cells stably expressing 
control and Ubiquilin 1 shRNAs were split into 6 well plates and reached 90% 
confluence. Then cells were pretreated in methionine/cysteine – free (starve) 
medium for 30 minutes. Then cells were treated with starve medium 
supplemented with 100uCi/ml [35S] methionine/cysteine for 20 minutes. The cells 
were then washed and lysed with RIPA buffer, and followed by 
immuniprecipitation with APP-CTF antibody.  
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        Cycloheximide degradation time course: This method has been 
described elsewhere previously [124]. SY5Y-APP-Gal4 cells stably expressing 
control and Ubiquilin 1 shRNAs were split into 6 well plates and reached 90% 
confluence. Then cells were treated with 30ug/ml cycloheximide for 0, 0.5, 0.75, 
1, 2, and 3 hours. Cells were washed and lysed with RIPA lysis buffer and 
applied to Western blotting analysis. Membrane was blotted with APP-CTF and 
β-actin specific antibodies. Mature and immature APP at each time point was 
normalized to the APP level at the time of 0h.  
         Biotinylation of cell surface proteins: Biotinylation of cell surface 
proteins was following the manufacture’s protocol and has been described 
previously [124]. SY5Y-APP-Gal4 cells that stably express control and Ubiquilin 1 
constructs were grown on the 60CM plates. Cells were washed 3 times and 
preincubated with 20 min in cold Mg2+/Ca2+ containing PBS. Then cells were 
incubated with 0.5mg/ml Sulfo-NHS-LC- Biotin (Pierce) for 30 minutes with gentle 
rocking at room temperature. Excess biotin was quenched with 0.1M glycine for 
20 minutes. Cells were then washed and lysed in RIPA lysis buffer and 
immunoprecipitated with streptavidin beads (Pierce) overnight at 4oC. Each 
sample was boiled at 95 oC for 5 min then applied to Western blotting analysis. 
Membrane was incubated with APP-CTF antibody.  
        MTT assay: The MTT assay was carried out using the MTT cell proliferation 
assay kit (ATCC BioproductsTM) according to the manufacturer’s instructions. 
Briefly, 5,000 cells were plated per well on the 96 well plates. Cells were 
challenged with 500μM H2O2 for 1 hour and 10ul MTT reagent was added to the 
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cells. After 3 hours of incubation at 37oC, 100ul detergent reagent was added to 
the cells. After the other 2 hours of incubation in darkness at 37oC, absorbance 
was read at 570nm using a spectrophotometer (Multiskan spectrum, Thermo 
Labsystems).  
        Caspase-3 activity assay: The Caspase-3 activity assay was following the 
manufacturer’s instructions (Molecular Probes®). The EnzChek® caspase-3 
assay kit #2 was utilized. In brief, 2×106 cells were seeded on a 6 well plate. After 
inducing apoptosis using 500μM H2O2 for one hour, cells were washed with 
phosphate-buffered saline (PBS) and lyzed using the lysis buffer provided by the 
manufacture, followed by centrifugation. Supernatant was transferred to a new 
white color 96-well plate and added with working solution containing caspase-3 
substrate. After covering the plate in dark for 30 minutes, fluorescence was read 
with the excitation/emission of ~496/520nm on a microplate fluorometer 
(Fluoscan Ascent FL, Thermo Labsystems).  
       Aβ measurement: Aβ measurement was following the method described 
previously [124]. In brief, Aβ40 and Aβ42 levels (pg/ml) were quantified using 
sandwich enzyme-linked immunosorbent (ELISA) assay. Each experiment was 
carried out at least in triplicate.  
       Statistical Analysis: Values in the text and figures are demonstrated as 
means ± standard errors from at least three independent experiments. Equal 
variance two-sample student’s t-test was utilized to compare two groups followed 
by Bonferroni’s test if multiple comparisons were examined within a single 
experiment. 
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Results 
       Ubiquilin 1 protein level is stably and robustly knocked down. shRNA 
constructs used here are plasmid-based and contain puromycin resistance 
marker. Cells stably expressing shRNA control or Ubiquilin 1 were generated by 
selecting for puromycin resistant clones. SY5Y-APP-Gal4 cells that stably 
express firefly luciferase were established by co-transfecting the APP-Gal4 and 
Gal4-UAS luciferase reporter components developed by Cao and Südhof [16] 
into SH-SY5Y, human neuroblastoma, cell line[182]. SY5Y-APP-Gal4 cells were 
transfected with non-silencing construct (not targeting any known genes or 
“control”) or Ubiquilin 1 construct (targeting Ubiquilin 1 mRNA or “shUBQLN1”). 
The multiple clonal cells that contain puromycin resistant constructs were 
selected and continued to grow in 1ug/ml puromycin and 200ug/ml G418 
containing media. We have five different shRNA constructs that target Ubiquilin 1 
as have been described previously. The construct of v2HS_254856 gave the 
most dramatic knock-down effect and has been routinely grown and frozen down 
in liquid nitrogen. Ubiquilin1 protein was robustly knocked down after re-thawing 
from liquid nitrogen (Figure1). Ubiquilin 1 protein knockdown was confirmed for 
every series of experiments. The knock-down constructs achieved using this 
method can maintain their knockdown effect for at least 3 months.  
       Ubiquilin 1 does not affect APP synthesis and degradation. Ubiquilin 1 
knockdown decreases APP steady state levels post-transcriptionally level in SH-
SY5Y cells[182]. To determine if the result is on APP synthesis or degradation, 
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we compared APP synthesis and degradation in cells expressing control or 
Ubiquilin 1 shRNA. Ubiquilin 1 knockdown results in around 10% increase in 
synthesized APP than the control, however, there was no statistical significance 
between them (P>0.05) (Figure 2A, 2B). To study if Ubiquilin 1 can alter APP 
degradation rate, cycloheximide time course experiment was carried out.  Control 
and shUbqln1 cells were incubated with cycloheximide for 0, 0.5, 0.75, 1, 2 and 3 
hours. Western blot analysis of APP revealed that mature and immature APP 
levels decreased at the same rate (Figure 2C, 2D). However at each time point, 
mature to immature APP is lower when comparing shUbqln1 to control cells 
(Figure 2E), which is consistent with our previous results in these cell lines[182]. 
Taken together, Ubiquilin 1 does not alter APP half life in SH-SY5Y cells, but 
alters mature to immature APP ratio.   
        Ubiquilin 1 knockdown decreases cell surface APP. We have previously 
reported that Ubiquilin 1 alters APP secretion differently between SH-SY5Y cells 
and HEK293 cells. In all these cell lines Ubiquilin 1 knock-down decreases APP 
steady state holoprotein levels. However, Ubiquilin 1 knock-down decreases 
sAPPα in SH-SY5Y cells and increases sAPPα in HEK293 cells. Cell surface 
biotinylation was employed to study what effect of Ubiquilin 1 knockdown on APP 
trafficking at the cell surface in SH-SY5Y cells. Ubiquilin 1 knockdown 
significantly decreased cell surface APP by around 15% (P<0.05) (Figure 3).  
       Ubiquilin 1 effects on APP metabolism are dependent on proteasome 
system. It was suggested that Ubiquilin 1 is an adaptor protein which delivers 
ubiquitinated proteins to the proteasome for degradation [173, 174, 176]. To 
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determine if Ubiquilin 1 mediated effects on APP metabolism are dependent on 
the proteasome, we inhibited proteasome utilizing MG132. Control and shUbqln1 
SY5Y-APP-Gal4 cells were treated with 10μM MG132 for 1 hour. Cell lysates 
were collected and applied to luciferase or Western blot analysis. Luciferase 
assay data revealed that MG132 treatment decreased AICD-mediated lucifease 
(P<0.01) on the control cells. However there was no significant difference in 
AICD-mediated luciferase activity in Ubiquilin 1 knockdown cells between the 
MG132 treatment and non-MG132 treatment (P>0.05) (Figure 4A). Using 
Western blot analysis to confirm this finding, when MG132 was applied to control 
cells, mature APP levels decreased (P<0.05) and immature APP level also 
decreased (P>0.05). However, MG132 treatment of Ubiquilin 1 knockdown cells 
did not alter levels of mature or immature APP levels (P>0.05) In addition, 
(Figure 4B, 4C, and 4D). Taken together, it is suggested that Ubiquilin 1 effect on 
APP processing is dependent on the proteasome system. In addition we 
observed that the chances in C83-Gal4 and AICD-Gal4 upon MG132 treatment.  
       Ubiquilin 1 alters cells viability and caspase-3 activity Because Ubiquilin 
1 is indicated to be involved in delivery proteins to the proteasome for 
degradation and prevent accumulation of misfolded proteins, down-regulating 
Ubiquilin 1 may decrease cell viability and lead cells go through apoptosis. To 
test this hypothesis, control and shUbqln1 stably knockdown SY5Y-APP-Gal4 
cells were challenged with 500μM H2O2 for 1 hour. Cell viability and caspase-3 
activity was then measured. Compared with control cells, Ubiquilin 1 knockdown 
cells significantly decreased cell viability (P<0.05) and elevated the caspase-3 
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activity (P<0.05) under the H2O2 stress (Figure 5A, 5B). Full length PARP is 
cleaved upon caspase-3 activation. Interestingly Ubiquilin 1 over-expression 
resulted in decreased levels of full length and cleaved PARP (Figure 5C).  
        Ubiquilin 1 degradation requires proteasome and lysosome It has not 
been investigated how Ubiquilin 1 is degraded. To determine how Ubiquilin 1 is 
degraded, we utilized MG132 and chloroquine to block the proteasome and 
lysosome degradation systems, respectively. Naïve SH-SY5Y cells were 
challenged with 10μM MG132 or 20μM chloroquine for 1h, and cell lysates were 
prepared and utilized for Western blotting analysis. MG132 and chloroquine 
dramatically increased Ubiquilin 1 protein levels respectively in naïve SH-SY5Y 
cells (Figure 6A). MG132 significantly increased Ubiquilin 1 protein levels about 5 
fold in SH-SY5Y cells (p<0.05). Chloroquine increased Ubiquilin 1 protein levels 
about 2 fold in SH-SY5Y cells, though it did not reach the statistical significance 
(Figure 6B). 
        Ubiquilin 1 over-expression decreases Aβ levels. Decreasing Aβ level is 
a therapeutic strategy for AD treatment, and proteins that could decrease Aβ 
level will be considered good therapeutic target. It has not been investigated if 
Ubiquilin 1 can decrease Aβ levels. To test the hypothesis that Ubiquilin 1 is an 
AD therapeutic target, naïve HEK-293 cells were transiently transfected with 
Ubiquilin 1 for 48h. Conditioned media was prepared and utilized for ELISA. 
Overexpression of Ubiquilin 1 decreased secreted Aβ40 level about 40% 
(p<0.05) and Aβ42 level up to about 60% (p=0.09) (Figure 7A). The ratio of Aβ42 
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to Aβ40 decreased up to 40% though it did not reach the statistical significance 
level (Figure 7B).  
         γ-Secretase inhibition increases Ubiquilin 1 protein levels Since it 
indicated that Ubiquilin 1 could be a potential AD therapeutic target, it is 
important to identify regulators and pathways that modulate Ubiquilin 1 activities. 
We and other groups have shown that Ubiquilin 1 modulates PS1 proteolysis and 
therefore γ-secretase activity, therefore, we determined to investigate if 
modulation of γ-secretase activity regulates Ubiquilin 1. L685,458,  a γ-secretase 
inhibitor,  was utilized to test its ability to modulate Ubiquilin 1. L685,458 
increased Ubiquilin 1 steady state protein levels about 5 fold (p<0.05) in naïve 
SH-SY5Y cells and about 4 fold in naïve HEK-293 cells (p<0.01) after 
normalizing to gel loading (Figure 8A, 8B, 8C, and 8D).  
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Discussion 
          Ubiquilin 1 modulates cell surface APP levels It has been indicated that 
Ubiquilin 1 modulates APP metabolism on a post-transcriptional level[124, 182]. 
To gain insight into the mechanism of the effects, we studied Ubiquilin 1 influence 
on APP half life using APP synthesis and degradation rate analysis in our 
previously reported SY5Y-APP-Gal4 stable cell line. Our results showed that 
Ubiquilin 1 does not alter APP half life, the same conclusion as what was 
observed in HEK293 cells [124]. A consistent finding was observed that 
mature/immature APP ratio from Ubiquilin 1 knock-down cells was lower than 
control cells with cycloheximide treatment. This was also consistent with what 
has been observed previously. Ubiquilin 1  knock-down has been shown to 
increase sAPPα and cell surface APP in HEK293 cells [124]. However we found 
previously that Ubiquilin 1 knock-down decreases sAPPα in SH-SY5Y cells. Here 
we also found Ubiquilin 1 knock-down decreases cell surface APP. The trend of 
sAPPα changes appears to be the same as that of cell surface APP. Taken 
together Ubiquilin 1 alters APP metabolism in a cell type dependent manner. 
Ubiquilin 1 does not alter APP half life in SH-SY5Y cells but it alters cell surface 
APP, as well as the mature to immature APP ratio. Knock-down of Ubiquilin 1 in 
SH-SY5Y cells decreases APP holoprotein levels and cell surface APP, as well 
as decreases mature to immature APP ratio.  
          Ubiquilin 1 modulation on APP is dependent on the proteasome 
Ubiquilin 1 has been shown to specifically deliver polyubiquitinated proteins to 
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the proteasome machinery for degradation. Interestingly some evidences 
suggested that Ubiquilin 1 functions do not require proteasome. In other words, 
Ubiquilin 1 functions could be dependent or independent on the proteasome 
system. The role of proteasome in Ubiquilin 1 functional regulation of APP 
metabolism has not been investigated. We found that Ubiquilin 1 effects on APP 
metabolism in SH-SY5Y cells are dependent on the proteasome system. MG132, 
a proteasome inhibitor, was applied to the SY5Y-APP-Gal4 cells that stably 
express control and Ubiquilin 1 shRNAs. MG132 decreased AICD-mediated 
luciferase activity, as well as mature and immature APP levels in control cells, but 
not in Ubiquilin 1 knock-down cells. We conclude that Ubiquilin 1 effects on APP 
metabolism are dependent on proteasome.  
        Ubiquilin 1 alters cells viability and caspase-3 activity Evidence has 
shown that Ubiquilin 1 is involved in the endoplasmic reticulum (ER) and UPS 
(Ubiquitin-proteasome system), which are important components of PQC (protein 
quality control) system [156, 165]. ER is the other eukaryotic organelle for protein 
folding and degradation. UPS is essential for many cellular processes, including 
the cell cycle, the regulation of gene expression, and responses to oxidative 
stress. A number of lines of experiments have shown that Ubiquilin 1 can alter 
intracellular toxicity and apoptosis [175, 187]. Ubiquilin 1 has also been 
implicated in the pathophysiology of cancer [167, 192].  
        Apoptosis, or programmed cell death, plays a critical role in development as 
well as in degenerative diseases, such as AD and cancer [191]. It is indicated 
Ubiquilin 1 is also involved in apoptosis from the report that Ubiquilin 1 could 
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alleviate the hypoxia induced apoptosis in SH-SY5Y cells. Recently members of 
the interleukin-1β-converting enzyme (ICE)/Ced-3 proteases (caspases) family of 
protease have been found to be pivotal mediators in apoptosis. It cleaves 
specifically Asp-Glu-Val-Asp (DEVD) amino acid sequence containing proteins, 
including Poly (ADP-ribose) polymerase (PARP), which is essentially involved in 
DNA repair in response to environmental and intracellular stress. There are no 
reports whether Ubiquilin 1 could alter caspase-3 activity and PARP protein 
levels.  
        To gain insight into the mechanism of how Ubiquilin 1 modulate cell viability, 
we found that Ubiquilin 1 knock-down decreased cell viability under H2O2 
treatment in SH-SY5Y cells. Ubiquilin 1 knock-down elevated caspase-3 activity 
under H2O2 treatment. Ubiquilin 1 over-expression decreased full length PARP 
and cleaved PARP levels. Taken together, Ubiquilin 1 alters caspase-3 activity 
and modulates PARP metabolism.   
           Uiquilin 1 degradation involves both proteasome and lysosome 
Intracellular and extracellular proteins are degraded through two major systems: 
the UPS and lysosome. UPS primarily degrades cytosolic regulatory proteins and 
misfolded proteins. Lysosome primarily degrades larger misfolded proteins or 
organelle through hydrolytic reactions in its acidic environment. Understanding β-, 
and γ-secretases activity and degradation pathway is important to understating 
APP and Aβ metabolisms. BACE is degraded through UPS and lysosome. All the 
four essential γ-secretase components (PS1, PEN2, NCT and APH1) have been 
shown to undergo UPS degradation[193-196]. BACE and NCT can also undergo 
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lysosome degradation[195, 197]. Uiquilin 1 degradation pathway has not been 
investigated. Here we found that Ubiquilin 1 undergo UPS and lysosome 
degradation pathway in SH-SY5Y cells.   
γ-Secretase inhibition increases Ubiquilin 1 protein levels Our data 
showed the first time that over-expression of Ubiquilin 1 decreases Aβ level, as 
well as the ratio of Aβ42/Aβ40, which also suggested that Ubiquilin 1 can be a 
therapeutic target for the intervention of AD. We also found that the γ-secretase 
inhibition by L685,458 could dramatically elevate Ubiquilin 1 steady state protein 
levels in SH-SY5Y and HEK293 cells. This finding strengthens the current 
therapeutic strategy to utilize γ-secretase inhibitors as intervention for AD.  
Moreover, it suggests that Ubiquilin 1 levels are regulated by the γ-secretase 
activity, a process that Ubiquilin 1 can also regulate by controlling PS1 
endoproteolysis. These results suggest that a regulatory circuit exists to 
coordinate the levels and activities of γ-secretase and Ubiquilin 1.  
         In summary we characterized the role of Ubiquilin 1 in APP metabolism and 
its involvement with the proteasome system. First we found that Ubiquilin 1 alters 
APP trafficking without affecting APP half-life. Next, Ubiquilin 1 interacts with 
proteasome system. Uiquilin 1 effects on APP metabolism are suggested to be 
dependent on the proteasome. Uiquilin 1 alters cell viability, as well as the 
caspase-3 activity and PARP levels. Moreover, Ubiquilin 1 undergo ubiquitin- 
proteasome system and lysosome. Finally, γ-secretase inhibition dramatically 
increases Ubiquilin 1 protein level, which suggests that a regulatory circuit exists 
to coordinate the levels and activities of γ-secretase and Ubiquilin 1. 
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Figures 
 
Figure 3-1: Uiquilin 1 protein level is robustly knocked down. SY5Y-APP-
Gal4 cells that express luciferase expressing constructs were transfected with 
scrambled shRNA sequence (not targeting any known genes; or “control”) or 
shUbqln1 sequence (targeting Ubiquilin 1 mRNA; or “shUBQLN1”) and selected 
with 2ug/ml puromycin for 7-10 days. This figure demonstrates that Ubiquilin 1 
protein level was still dramatically knocked down after freezing and thawing from 
the liquid nitrogen. β-Actin serves as a loading control.  
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Figure 3-2: Ubiquilin 1 knock-down does not change APP half life, but 
changes mature and immature ratio.  A. Ubiquilin 1 knockdown does not 
alter APP synthesis rate. SY5Y-APP-Gal4 cells stably expressing control and 
Ubiquilin 1 shRNAs were pulsed for 30 minutes with [35S]-Met. Total protein 
lysates were immunoprecipitates with the APP-CTF antibody and exposed for 
phosphorimaging screen for quantification. A protein that is about 35 kDa size 
and non-specific to APP antibody served as the loading control. B. Normalized 
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densitometry for figure A. There is no statistical difference between control and 
shUbqln1 for the newly synthesized APP (P>0.05). C. Ubiquilin 1 knockdown 
does not change APP degradation rate. SY5Y-APP-Gal4 cells stably 
expressing control and Ubiquilin 1 shRNAs were treated with 30μM 
cycloheximide for 0, 0.5, 0.75, 1, 2, and 3 hours. Cells lysates were collected at 
each time point and utilized for Western blotting analysis. D. Normalized 
densitometry for figure C. Ubiquilin 1 knock down does not alter APP 
degradation rate. E. Calculated mature APP to immature APP ratio from 
densitometry data of figure C.  Mature to immature APP ratio from Control was 
higher than shUbqln1 at each time point during the cycloheximide treatment.  
 135
A                                                                    B  
       
 
Figure 3-3: Ubiquilin 1 knockdown decreased cell surface APP. A. SY5Y-
APP-Gal4 cells stably expressing control and Ubiquilin 1 shRNAs were 
biotinylated with Sulfo-NHS-LC-biotin for 30 minutes at 4OC, 
immununoprecipated with streptavidin-agarose beads and applied to Western 
blotting analysis. Ubiquilin 1 knock-down decreased cell surface APP levels. B. 
Normalized densitometry. Ubiquilin 1 knock-down significantly decreased cell 
surface APP levels (P<0.05). 
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Figure 3-4: Ubiquilin 1 effect on APP metabolism modulation is dependent 
on proteasome system. A. 1h treatment of 10μM MG132 significantly 
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decreased luciferase activity in SY5Y-APP-Gal4 cells stably transfected with 
control shRNA (p<0.01). Mock contained the same amount of DMSO as MG132 
sample. B. 1h treatment of 10μM MG132 did not change luciferase activity in 
SY5Y-APP-Gal4 cells stably transfected with Ubiquilin 1 shRNA (p>0.05). C. 
MG132 decreased mature and immature APP steady state protein levels in 
SY5Y-APP-Gal4 cells stably expressing control shRNAs. D. Normalized 
densitometry figure C. MG132 significantly decreased mature APP protein levels, 
but did not significantly alter immature APP protein levels. E. MG132 did not 
decrease mature and immature APP steady state protein levels in SY5Y-APP-
Gal4 cells stably expressing Ubiquilin 1 shRNA. F. Normalized densitometry for 
figure E. MG132 did not change mature and immature APP protein levels 
(p>0.05).  
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Figure 3-5: Down-regulation of Ubiquilin 1 decreases cell viability, as well 
as elevates caspase-3 activity. A. Ubiquilin 1 knock-down significantly 
decreased cell viability in SY5Y-APP-Gal4 cells utilizing the MTT assay (p<0.05). 
SY5Y-APP-Gal4 cells stably expressing control and Ubiquilin 1 shRNAs were 
incubated with 500μM H2O2 for 1 hour, and then subjected to MTT assay to 
measure cell viability. B. Ubiquilin 1 knock-down significantly elevates caspase-3 
activity. SY5Y-APP-Gal4 cells stably expressing control and Ubiquilin 1 shRNAs 
were incubated with 500μM H2O2 for 1 hour, and then utilized in a caspase-3 
activity assay (p<0.05). The caspase-3 activity of shUbqln1 cells was compared 
to control cells. C. Ubiquilin 1 over-expression decreased PARP protein levels.  
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SY5Y-APP-Gal4 cells were transiently transfected with Ubiquilin 1 over-
expression plasmid. Cell lysates were prepared 2 days post transfection and 
applied to Western blotting analysis. The first antibody was anti PARP which can 
detect both the full length (119 kDa) and cleaved PARP protein (89 kDa). 
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Figure 3-6: Ubiquilin 1 degradation requires proteasome and lysosome. A. 
MG132 and chloroquine dramatically increase Ubiquilin 1 protein levels 
respectively in naïve SH-SY5Y cells. Naïve SH-SY5Y cells were treated with 
10μM MG132 or 20μM chloroquine for 1 hour, and then cell lysates were 
collected and applied to Western blotting analysis. β-actin was utilized as the 
loading control. B. Normalized densitometry for figure A. MG132 significantly 
increased Ubiquilin 1 protein levels about 5 fold in SH-SY5Y cells (p<0.05). 
Chloroquine increased Ubiquilin 1 protein levels about 2 fold in SH-SY5Y cells, 
though it did not reach the statistical significance. 
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Figure 3-7: Ubiquilin 1 decreases Aβ levels, as well as Aβ42/Aβ40 ratio. 
Naïve HEK293 cells were transiently with Ubiquilin 1 over-expression plasmids. 
Conditioned media was prepared 48 h post trasnsfection and utilized for Aβ 
ELISA assay. Ubiquilin 1 over-expression significantly decreases Aβ40 (P<0.05) 
(Figure A). Ubiquilin 1 over-expression decreases Aβ42 levels, as well as 
Aβ42/Aβ40 ratio, though statistically significance was not reached (Figure A & B).  
 142
 
A                                                                    B 
      
C                                                                    D 
      
 
Figure 3-8: γ-secretase inhibition increases Ubiquilin 1 protein levels. A. 
L685,458 dramatically increased Ubiquilin 1 protein levels in SH-SY5Y cells. 
Naïve SH-SY5Y cells were treated with 5μM L685,458 for 1 hour. Cell lysates 
were prepared and applied to Western blotting analysis. β-Actin served as the 
loading control. B. Normalized densitometry for figure A. L685,458 significantly 
increased Ubiquilin 1 protein levels about 5 fold in SH-SY5Y cells (p<0.05). C. 
L685,458 dramatically increases Ubiquilin 1 protein levels in HEK-293 cells. D. 
Similar to A, naïve HEK293 cells were treated with 5μM L685,458 for 1 hour. Cell 
lysates were prepared and applied to Western blotting analysis. D. Normalized 
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densitometry for figure C. L685,458 significantly increase Ubiquilin 1 protein 
levels about 4 fold in naïve HEK293 cells (p<0.01). 
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CHAPTER 4 
 
Discussion and future directions 
 
 
  In the first chapter, I introduced the background and status of Alzheimer’s 
disease (AD) research. Evidence from genetics, molecular biology and 
biochemistry studies indicates that APP metabolism is a central event in AD; 
however, the underlying mechanism is not completely understood. We aim to 
identify novel APP metabolism regulators and therefore identify therapeutic 
targets for AD. In the second chapter, I described the establishment and 
validation of an AICD-mediated assay to identify novel APP metabolism 
regulators in my laboratory. Next in the third chapter I explored our screening 
assay on one of the chromosomal regions linked to AD. A number of putative 
APP metabolism regulators have been identified and their functional properties 
are undergoing further characterization. Here I will further discuss the results of 
my screening assay, as well as one of the “hits” I have further functionally 
characterized.  
Utilization of AICD mediated assay to identify novel APP metabolism 
regulators APP metabolism is considered a central event of AD and the 
traditional way to investigate APP metabolism is to measure Aβ levels. 
Compared to the approach of Aβ measurement, our assay has several 
advantages. The first one is that the cost of our assay is low. The readout of our 
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AICD-mediated assay is luciferase, which is usually measured on a 96 well plate 
and the cost is at least 5 fold lower than the Aβ measurement using Enzyme-
Linked ImmunoSorbent Assay (ELISA). The second advantage is the speed. 
Similar to the first reason, luciferase assay takes less than 1 hour after the lysate 
preparation. However it takes more than 5 hours measuring Aβ levels utilizing 
ELISA after collecting conditioned media. The third advantage is reliability. To 
evaluate the quality of our assay, the Z parameter was utilized which takes into 
account the data range and variation. All the known APP metabolism regulators 
revealed a greater than 0.5 value of Z factor. This suggests that our assay is 
reliable and robust to detect APP metabolism regulators. The last but not the 
least advantage is the precision. Since lucferase is utilized as the alternative 
representative of the protein activity of AICD-Gal4, we calculated their correlation 
and regression relationship using known APP metabolism regulators. The data 
from Figure 2-8 demonstrates that these two factors represent each other, and 
luciferase represents AICD-Gal4 protein level precisely. Taken together I am 
confident that our assay is robust and reliable to identify novel APP metabolism 
regulators.  
I utilized the AICD-based screening assay to test genes on chromosome 
9q22 which is a region linked to AD. There are 112 known genes in this region 
and the Drexel University RNAi resource center maintains shRNA constructs that 
target 83 genes. In the screening approach, the negative controls are non-coding 
shRNA (its sequence does not match any known mRNA sequences in human) 
and eGFP shRNA (enhanced green fluorescence protein; its protein is not 
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expressed in the assay cells). The positive controls are APP and ADAM10 
shRNAs that are confirmed to alter AICD-mediated luciferase activities. For the 
data analysis, we used two sample, two-tail, t-test followed by sequential 
Bonferroni test to correct comparisons from multiple groups. To further lower the 
potential of false positive errors, we confirmed each gene as a “hit” only if we 
observed the effects in multiple constructs or the same construct in multiple 
independent experiments (for single construct genes). Using these rigorous 
criteria, we identified 11 “hits”. These “hits” require further functional 
characterization because of the “off-target” effect of shRNAs. Over-expression, 
Western blotting analysis and other experiments will be carried out for further 
characterization.  
Characterization of Ubiquilin-1 as an APP metabolism regulator     
Ubiquilin 1 is one of the “hits” that modulate APP metabolism. It belongs to the 
Ubiquilin family which has 3 other Ubiquilin 1 homologues: Ubiquilin 2, Ubiquilin 3, 
and Ubiquilin 4. They share similar functional structures and all contain an UBA 
(ubiquitin-asociated domain) on the N-terminus and an UBL (ubiquitin-like 
domain) on the C-terminus. Ubiquilin family proteins have been shown to interact 
with a number of proteins that carry out various functions, including ER-
associated quality control and degradation (ERQD or ERAD) [155, 169, 170], 
DNA repair[199], spindle pole duplication[200-203] , cell cycle arrest[201], cell 
adhesion[204] and apoptosis[175]. Ubiquilin family proteins interact with more 
than 10 proteins. Some proteins are dependent on the proteasome degradation 
[144, 174, 175]; some seem to be independent of the proteasome 
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degradation[176], and others are unidentified whether they need proteasome or 
not[172]-[177]. Ubiquilin family proteins have also been implicated in the 
pathophysiology and pathogenesis of Alzheimer’s disease[125, 127, 137, 181, 
182], PolyQ diseases[187] [186]., and cancer[188] [189] [167]. Arising from all 
these puzzling and multiple-aspect facts, the overall Ubiquilin function seems to 
be protein quality control (PQC) and the underlying mechanism is still not fully 
understood. This is discussed in detail in the third chapter.   
 
Figure 4-1 Route of protein trafficking. Molecular Biology of Cell, 4th edition, 
Page 665, Garland Science. 
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Figure 4-2 APP synthesis and degradation. 
 
  I focused on the study of Ubiquilin 1 mediated APP metabolism regulation 
regardless of the other proteins that Ubiquilin1 interact with. Figure 4-1 shows the 
general protein trafficking. Figure 2 illustrates the APP synthesis and degradation 
pathway, which include the secretory pathway and the endocytic pathway. APP is 
a type I transmembrane glycoprotein and it is present on almost every 
intracellular organelle and plasma membrane (or cell membrane). It is suggested 
to function in neuroprotection, synaptic transmission, signal transduction, and 
axonal transport [101, 102].  APP maturation and trafficking was shown in Figure 
4-2. Upon being transcribed and translated, APP protein undergoes N-
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glycosylation in the ER and cis-Golgi.  Then it undergoes O-glycosylation in 
medial- , trans-Golgi and trans-Golgi network (TGN) to become mature. Mature 
APP is transported to mitochondria, peroxisomes and other organelles, as well as 
plasma membrane by secretory vesicles. If the plasma membrane APP is not 
cleaved by α-, or β- secretases, it will be reinternalized within clathrin-coated 
vesicles to an endosomal/lysosomal degradation pathway.  
    During the APP cleavage pathway, the initial cleavage by either α- or β- 
secretase is the rate-limiting step. β-, and γ- secretase are present on almost 
every intracellular organelle and plasma membrane. BACE has maximal activity 
at acidic pH, and its activity is highest in the acidic subcellular compartments, 
including the Golgi apparatus and endosomes, which are the places where most 
Aβ is generated[198]. α-secretase has the highly cleavage activity on the plasma 
membrane. Therefore, Aβ is generated intracellularly and extracellularly. 
Molecules that modulate APP trafficking in these organelles and plasma 
membrane may change the Aβ production and modulate AD risk. My data show 
that Ubiquilin 1 alters APP maturation and trafficking to the cell surface, as well 
as presenilin 1 endoproteolysis. The underlying mechanism is still not known. 
Gandy et al showed the familial AD mutant PS1 shifted the holoAPP and APP 
CTFs toward TGN in vivo[198]. It is not sure whether, and possibly to what level, 
the altered PS1 endoproteolysis affect APP maturation and trafficking. This is a 
line of investigation that will be further studied whether Ubiquilin 1 alters APP 
trafficking to the TGN or endosome. The second future study is to investigate 
whether proteasome blockage affects Ubiquilin 1 effects on PS1 endoproteolysis. 
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The third and also important future research question is to study the underlying 
mechanism of how Ubiquilin 1 alters APP maturation and trafficking. This line of 
investigation could be carried out by inhibiting or stimulating protein secretory 
and/or endocytic pathway when Ubiquilin 1 is up-, or down-regulated. The fourth 
line of future research is to construct an Ubiquilin 1 interaction network and study 
the mechanism of how Ubiquilin 1 interacts with so many proteins with various 
functions. It will be also interesting to investigate whether alteration of other 
Ubiquilin 1 interacting proteins may change APP metabolism. Last but not least is 
the hypothesis of using Ubiquilin family proteins as therapeutic targets for AD, 
and possibly also for other neurodegenerative disorders and cancers. It will be 
crucial to investigate its global effects on other interacting proteins.  
     Functional characterization of other APP metabolism regulators 11 
genes have been identified from chromosome 9q22 using our AICD-mediated 
luciferase assay. Table 4-1 shows their name and key functions. Most recently 
four of them (CTSL, NTRK2, SHC3 and UBQLN1) have been implicated in AD 
risk or APP metabolism. Here I show, for the first time, that the other 7 genes 
could be involved in APP metabolism.  
Down-regulation of five genes decreased AICD-mediated luciferase and 
therefore they are considered positive APP metabolism regulators: CTSL 
(Cathepsin L), CTSL2 (Cathepsin L2), FRMD3 (FERM domain containing 3), 
NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), and UBQLN1 (Ubiquilin 
1). Here I will briefly describe their essential functions and emphasize their 
involvement in APP metabolism and disorders.  
 151
CTSL (Cathepsin L, or CTSL1) is a papain-type cysteine proteinase whose 
activity is present in the lysosome and clathrin-coated vesicles[205, 206], and is 
capable of initiating the processing of APP or its fragments[206], and possibly 
involved in the processing of APP to Aβ [207].  
Differently from CTSL, the CTSL2 gene encodes the cysteine protease 
cathepsin V (Cat V), also called L2. It is involved in antigen processing and 
antigen presentation by MHC class II molecules [208]. Polymorphisms in CTSL2 
gene show association with type 1 diabetes and early-onset myasthenia 
gravis[208].  
FRMD3 (Ferm domain containing protein 3) protein is a member of the 
protein 4.1 superfamily, which are characterized by the presence of a conserved 
FERM (Four.1 protein, Ezrin, Radixin, Moesin) domain and  a spectrin/actin 
binding domain (SABD). These proteins function to link cell surface glycoproteins 
to the actin cytoskeleton [209]. Recently FRMD3 is implicated in the origin and 
progression of lung cancer[210].  
NTRK2 (Neurotrophic tyrosine receptor kinase, type 2), also named as 
TRKB (Tyrosine receptor kinase, type B), belongs to the NTRK or TRK protein 
family, which includes NTRK1/TRKA, NTRK2/TRKB, and NTRK3/TRKC. The 
family proteins NTRK1, NTRK2 and NTRK3 bind three kinds of neurotrophins, 
NGF (Nerve growth factor), BDNF (Brain-derived neurotrophic factor) and NT-3 
(neurotrophin-3) with high affinity, respectively. The ligand and receptor binding 
activates a wide range of downstream intracellular cascades, regulating neuronal 
development and plasticity, long-term potentiation, and apoptosis [211-213]. Most 
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recently NTRK2 is implicated to be a genetic susceptibility gene contributing to 
AD pathology[211].  
UBQLN1 (Ubiquilin 1), an UBA (ubiquitin-asociated domain) and an UBL 
(ubiquitin-like domain) containing protein, has been indicated to be an adaptor 
protein transporting polyubiquitinated proteins toward proteasome for 
degradation. A polymorphism in UBQLN1 has been shown to increase AD 
risk[137]. Ubiquilin 1 protein belongs to the Ubiquilin protein family which 
contains 4 members that are primarily involved in protein degradation and protein 
quality control. It functions to modulate protein steady state levels, or maturation, 
or half life levels and influences more than 10 proteins including APP, dependent 
or independent of the proteasome[124, 127, 143, 173, 175, 182]. Ubiquilin 1 
modulates APP maturation, as well as PS1 endoproteolysis[127]. More Ubiquilin 
1 details are described in chapter 3.  
Down-regulation of six genes identified using our AICD-mediated 
luciferase assay increased the luciferase activity, and therefore they are 
considered negative APP metabolism regulators: KIF27 ( Kinesin family member 
27), NR4A3 (Nuclear receptor subfamily 4, group A, member 3), PPP3R2 
(Protein phosphatase 3, regulatory subunit B, beta isoform), SPTLC1 ( Serine 
palmitoyltransferase, long chain base subunit 1), SHC3 (Src homology 2 domain-
containing transforming protein C3), and TMOD1 (Tropomodulin 1). Next I will 
briefly describe their essential functions and emphasize their involvement in APP 
metabolism and disorders.  
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KIF27 (Kinesin family member 27) is the mammalian homolog of the 
Drosophila costal2 (cos2) gene which encodes a kinesin-related protein [214]. In 
flies, cos2 is involved in the Hedgehog (Hh) signal transduction pathway [215-
217], which is essential in the embryonic patterning and development in the 
Drosophila and mammals[218]. The hh gene itself is a segment polarity gene 
[219] that encodes the secreted ligand required to activate the Hedgehog 
signaling pathway. Cos2 protein is bound to microtubules in a complex and is 
released in a Hh-dependant manner [214, 220] . The complex contains Ser/Thr 
kinase Fused (Fu), as well as the Suppressor of Fused (Su (fu)) [214, 220].  
NR4A3 (Nuclear receptor subfamily 4, group A, member 3) belongs to a 
NGFIB-like (nerve growth factor IB-like) subfamily of the NHR (nuclear hormone 
receptor) family. The subfamily has identified three members including NR4A1 
(or NGFIB) , NR4A2 (or NURR1/nucclar receptor related 1), and NR4A3 ( or 
NOR1/neuron-derived orphan receptor 1) . These three members share similar 
structural features and have yet known natural ligands. They are transcriptional 
factors that function through activation and subsequent induction of the 
downstream pathways, and are essential in the temporal regulation of genes and 
implicated in the cell survival, apoptosis and tissues development[221]. NR4A2 
and NR4A3 are indicated to be critical tumor suppressors of myeloid 
leukemogenesis[222].  
PPP3R2 (also known as PP2BB2) (Protein phosphatase 3, regulatory 
subunit B, beta isoform) is one of the two isoforms of PPP3R (Calcineurin B), the 
regulatory subunit of PPP3 (protein phosphatase 3, or Calcineurin, or PP2B) 
 154
[223]. PPP3 is a serine/threonine protein phosphatase, and is a heterodimer 
composed of PPP3C (Calcineurin A, the PPP3 catalytic subunit) and PPP3C, 
Calcineurin A) and PPP3R. PPP3R is an EF-hand Ca2+ binding protein and 
plays critical roles in many calcium-mediated signal transduction pathways. 
PPP3R has two isoforms, PPP3R1 (or PP2BB1) and PPP3R2 (or PP2BB2). 
Differently from PPP3R1 which is ubiquitously expressed in different tissues, 
PPP3R2 seems to be exclusively expressed in testis[223]. I expect that PPP3R2 
knockdown should not alter APP metabolism in our neuroblastoma SH-SY5Y cell 
line. However, AICD-mediated luciferase results showed that PPP3R2 
knockdown increased luciferase. Confirmative evidence can be obtained from 
over-expression experiments and Western blotting analysis.  
SPTLC1 (Serine palmitoyltransferase, long chain base subunit 1) is one 
heterodimer subunit of the mammalian SPT protein. A third subunit, SPTLC3, a 
homolog of SPTLC1 and SPTLC2 , has also been implicated in the SPT 
complex[224, 225]. SPT protein complex catalyses the rate-limiting step for the 
synthesis of sphingolipids, which are essential in cell membrane formation, signal 
transduction, cholesterol homeostasis, and lipoprotein metabolism. All these 
functions can modulate atherosclerotic and cardiovascular disease development. 
Lipoproteins have also been implicated in AD[226]. Apolipoprotein E (APOE) is 
the only gene in which a polymorphism has been confirmed to increase AD 
risk[70, 75]. 
SHC3 (Src homology 2 domain-containing transforming protein C3; or 
ShcC; or N-Shc; or Rai) is one among the more than 100 SH2 domain containing 
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proteins and is one the three mammalian Shc genes including ShcA (or Shc), 
ShcB (or Sli/SCK), and ShcC. Its cytoplasmic signal transducers are 
characterized by the unique PTB-CH1-SH2 modular organization (PTB: 
phosphotyrosine-binding domains; CH: collagen homology region; SH: src 
homology 2).  Shc3 expression is restricted to neuronal cells and regulates the 
number of postmitotic sympathetic neurons[227]. It is important in the MAPK and 
PI3K signaling pathways, as well as Ret-dependent and -independent survival 
signals[227]. Recently it has been implicated in the APP metabolism. Shc3, as 
well as Shc 1 and Fe65 (APBB1) are APP adapter proteins and can bind to and 
interact with the conserved YENPTY motif in the APP-C terminus. Xie et al 
recently reported that down-regulation of ShcC led to the reduction of APP-CTFs 
and Aβ, as well as the reduction of BACE in H4 human neuroglioma cells. 
Therefore, they suggested that ShcC could be a therapeutic target against 
AD[228].  
TMOD1 (Tropomodulin 1) along with 3 tropomodulin proteins (TMOD2, 3, 
and 4), belongs to the family of tropomodulin. It is a tropomyosin-binding protein 
and caps the slow-growing (pointed) end of the actin filament, therefore regulates 
its dynamics. Tropomodulin is essential  for determining cell morphology, cell 
movement, and muscle contraction[229, 230]. 
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CTSL: Cathepsin L Potential contribution of the lysosomal compartment in the processing 
of  APP to Aβ 
CTSL2: Cathepsin L2 A cysteine protease; proteolysis and peptidolysis; cathepsin L activity  
FRMD3: FERM domain 
containing 3  
A multifunctional protein essential for maintaining erythrocyte shape 
and membrane mechanical properties.  
KIF27: kinesin family member 
27 Kinesin_motor 
NTRK2: Neurotrophic 
tyrosine kinase, receptor, type 
2 
Receptor for brain-derived neurotrophic factor (BDNF), neurotrophin-
3 and neurotrophin-4/5; involved in the development and/or 
maintenance of the nervous system. Indicated to be an AD suspitible 
gene.  
NR4A3: nuclear receptor 
subfamily 4, group A, member 
3 
Neuron-derived orphan receptor; Mitogen-induced nuclear orphan 
receptor 
PPP3R2: Protein phosphatase 
3 (formerly 2B), regulatory 
subunit B, beta isoform  
Regulatory subunit of calcineurin, a calcium-dependent, calmodulin 
stimulated protein phosphatase. calcium ion binding; MAPK signaling 
pathway; Apoptosis; Long term memory 
SPTLC1: serine 
palmitoyltransferase, long 
chain base subunit 1  
Catalytic activity: Palmitoyl-CoA + L-serine = CoA + 3-dehydro-D- 
sphinganine + CO(2). Belongs to the class-II pyridoxal-phosphate-
dependent aminotransferase family. 
SHC3: Src homology 2 
domain-containing 
transforming protein C3  
Signaling adapter that couples activated growth factor receptors to 
signaling pathway in neurons. Signal transduction pathways of 
neurotrophin-activated Trk receptors in cortical neurons. Modultes 
APP metabolism and Aβ levels.  
TMOD1: Tropomodulin 1 
Tropomodulin is highly concentrated at the postsynaptic domain of 
human and rat neuromuscular junctions; tropomyosin binding; 
cytoskeleton; organization and biogenesis; actin binding  
UBQLN1: Ubiquilin 1 
In vivo protein degradation, modulates accumulation of presenilin 
proteins, and is found in lesions associated with Alzheimer's and 
Parkinson's disease.  
   
Table 4-1: APP metabolism regulators identified utilizing the AICD-mediated 
luciferase assay. 
Summary Taken together, we have established and validated an AICD-
Gal4 based functional assay in SH-SY5Y cells. Using this assay in combination 
with RNAi, we have developed a genetic screen to identify regulators of APP 
metabolism. This screen accurately, robustly, and easily measures changes in 
AICD-Gal4 levels. We demonstrate that these AICD-Gal4 levels can be altered 
by pharmacologic or genetic modulation of genes that directly regulate APP 
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levels, AICD trafficking/signaling, APP maturation, and APP proteolysis. Using 
this approach, we identified 11 genes on chromosome 9q22, a region linked with 
AD high risk. We further characterized the ubibquilin 1 mediated APP metabolism. 
We show that Ubiquilin 1 can regulate AICD-Gal4 levels in SH-SY5Y cells. 
Ubiquilin 1 regulates AICD-Gal4 levels by modulating APP levels, the ratio of 
mature to immature APP, and PS1 endoproteolysis. Interestingly, alteration of 
PS1 activity also changes Ubiquilin 1 protein levels. We also demonstrate that 
the effect of Ubiquilin 1 on APP metabolism is dependent on proteasome system. 
Ubiquilin 1 protein undergoes proteasome and lysosome degradation pathways. 
Taken together, the results demonstrate that this genetic screen is capable of 
identifying APP metabolism regulators that can modulate the APP proteolytic 
processing, APP maturation, APP levels, and AICD trafficking/signaling.  
Furthermore, we suggest that there exists a regulatory circuit to coordinate the 
levels and activities of γ-secretase and Ubiquilin 1. Characterization of other 10 
“hits” through our AICD-mediated assay is required to understand their 
involvement in the APP metabolism.  
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